


APOL1 C-Terminal Variants May Trigger Kidney Disease through Interference with APOL3 Control of Actomyosin

Graphical Abstract



Authors

Sophie Uzureau, Laurence Lecordier, Pierrick Uzureau, ..., Christophe Erneux, David Pérez-Morga, Etienne Pays

Correspondence

epays@ulb.ac.be

In Brief

Uzureau et al. propose a molecular explanation for the linkage between resistance to sleeping sickness and high risk of kidney disease in African individuals expressing APOL1 variants. These variants resist neutralization by *T. rhodesiense* SRA and kill the parasite, but they also indirectly trigger podocyte actomyosin reorganization through interaction with APOL3, inactivating the NCS-1-PI4KB complex.

Highlights

- C-terminal helix alteration unfolds APOL1, increasing APOL1 interaction with APOL3
- APOL3 binds to NCS-1, promoting NCS-1-PI4KB interaction and PI4KB activation
- C-terminal APOL1 variants interfere with APOL3-NCS-1 interaction, inactivating PI4KB
- PI4KB inactivation occurs in podocytes from kidney disease patients with APOL1 variants



APOL1 C-Terminal Variants May Trigger Kidney Disease through Interference with APOL3 Control of Actomyosin

Sophie Uzureau,¹ Laurence Lecordier,¹ Pierrick Uzureau,² Dorle Hennig,³ Jonas H. Graversen,³ Fabrice Homblé,⁴ Pepe Ekulu Mfutu,⁵ Fanny Oliveira Arcolino,⁵ Ana Raquel Ramos,⁶ Rita M. La Rovere,⁷ Tomas Luyten,⁷ Marjorie Vermeersch,⁸ Patricia Tebabi,¹ Marc Dieu,⁹ Bart Cuyppers,^{10,11} Stijn Deborggraeve,¹⁰ Marion Rabant,¹² Christophe Legendre,¹³ Søren K. Moestrup,^{3,14} Elena Levchenko,⁵ Geert Bultynck,⁷ Christophe Erneux,⁶ David Pérez-Morga,^{1,8} and Etienne Pays^{1,15,*}

¹Laboratory of Molecular Parasitology, IBMM, Université Libre de Bruxelles, 6041 Gosselies, Belgium

²Laboratory of Experimental Medicine (ULB222), CHU Charleroi, Université Libre de Bruxelles, Montigny le Tilleul, Belgium

³Department of Molecular Medicine, Cancer and Inflammation Research, University of Southern Denmark, 5000 Odense C, Denmark

⁴Laboratory of Structure and Function of Biological Membranes, Université Libre de Bruxelles, 1050 Brussels, Belgium

⁵Pediatric Nephrology, University Hospital Leuven, 3000 Leuven, Belgium

⁶Institute of Interdisciplinary Research in Human and Molecular Biology, Campus Erasme, Université Libre de Bruxelles, 1070 Brussels, Belgium

⁷Laboratory of Molecular and Cellular Signalling, KU Leuven, Herestraat 49, 3000 Leuven, Belgium

⁸Center for Microscopy and Molecular Imaging (CMMI), Université Libre de Bruxelles, 6041 Gosselies, Belgium

⁹URBC-Narilis, University of Namur, 5000 Namur, Belgium

¹⁰Biomedical Sciences Department, Institute of Tropical Medicine, 2000 Antwerpen, Belgium

¹¹Adrem Data Lab, Department of Mathematics and Computer Science, University of Antwerp, 2000 Antwerpen, Belgium

¹²Adult Nephrology-Transplantation Department, Paris Hospitals and Paris Descartes University, 75006 Paris, France

¹³Pathology Department, Paris Hospitals and Paris Descartes University, 75006 Paris, France

¹⁴Department of Biomedicine, University of Aarhus, 8000 Aarhus, Denmark

¹⁵Lead Contact

*Correspondence: epays@ulb.ac.be

<https://doi.org/10.1016/j.celrep.2020.02.064>

SUMMARY

The C-terminal variants G1 and G2 of apolipoprotein L1 (APOL1) confer human resistance to the sleeping sickness parasite *Trypanosoma rhodesiense*, but they also increase the risk of kidney disease. APOL1 and APOL3 are death-promoting proteins that are partially associated with the endoplasmic reticulum and Golgi membranes. We report that in podocytes, either APOL1 C-terminal helix truncation (APOL1Δ) or APOL3 deletion (APOL3KO) induces similar actomyosin reorganization linked to the inhibition of phosphatidylinositol-4-phosphate [PI(4)P] synthesis by the Golgi PI(4)-kinase IIIB (PI4KB). Both APOL1 and APOL3 can form K⁺ channels, but only APOL3 exhibits Ca²⁺-dependent binding of high affinity to neuronal calcium sensor-1 (NCS-1), promoting NCS-1-PI4KB interaction and stimulating PI4KB activity. Alteration of the APOL1 C-terminal helix triggers APOL1 unfolding and increased binding to APOL3, affecting APOL3-NCS-1 interaction. Since the podocytes of G1 and G2 patients exhibit an APOL1Δ or APOL3KO-like phenotype, APOL1 C-terminal variants may induce kidney disease by preventing APOL3 from activating PI4KB, with consecutive actomyosin reorganization of podocytes.

INTRODUCTION

Like human resistance to malaria is associated with inherited sickle cell anemia, innate immunity to sleeping sickness is genetically linked to chronic kidney disease (CKD) (Genovese et al., 2010). This unexpected connection involves apolipoprotein L1 (APOL1), a protein found only in primates, which belongs to a family of apoptotic proteins involved in cell death induced by viral stimuli (Nichols et al., 2015; Uzureau et al., 2016; Vanhullebeke and Pays, 2006). APOL1 is the only family member containing an N-terminal signal peptide for secretion, and it is also the only member with a clearly identified function. The secreted fraction of APOL1 is the trypanolytic factor of human serum, able to kill different subspecies of the African parasite *Trypanosoma brucei*, but not the sleeping sickness agents *T. b. rhodesiense* and *T. b. gambiense* (Pays et al., 2014; Vanhamme et al., 2003). APOL1 is a pore-forming protein requiring acidic pH for insertion into membranes and exhibiting cation channel activity at neutral pH (Pérez-Morga et al., 2005; Thomson and Finkelshtein, 2015) (APOL1 structure in Figure 1A). Trypanolytic activity results from the induction of an apoptotic-like process in the parasite following the intracellular transfer of APOL1-containing endosomal membranes to the mitochondrion (Vanwallegheem et al., 2015). *T. b. rhodesiense* neutralizes the toxicity of APOL1 through the interaction of its serum resistance-associated (SRA) protein with the C-terminal leucine zipper (LZ) helix of APOL1 (SRA-interacting domain [SRID] in Figure 1A) (Lecordier et al., 2009; Pays et al., 2014; Vanhamme et al., 2003). The






Figure 1. APOLs Are Membrane-Associated Proteins Involved in Poly(I:C)-Induced Podocyte Death

(A) APOL1 domains and mutations relevant for the study. SP, signal peptides (amino acids [aa] 1–27 and 28–53), PFD, pore-forming domain (aa 60–235), MAD, membrane-addressing domain (aa 238–304), hinge (aa 305–339), SRID, SRA-interacting domain (aa 340–398), HC/LZ 1/2, pairs of associated hydrophobic cluster and leucine zipper (aa 79–88/100–122 and 343–354/368–392), SID1/2, smallest interacting domains defined by Y2H interactions with the indicated bait sequences (aa 78–121 and 346–390).

(B) APOLs immunodetection in total extracts from cells treated or not with poly(I:C). The arrows point to APOL3, located under a non-specific band. The bottom panel shows the immunodetection of endogenous V5- or TriFLAG-tagged APOL3 in the relevant cell lines. Actin immunodetection serves as a loading control.

(C) Poly(I:C)-induced cell death in the different podocyte lines (error bars, SDs). See Figure S1 for additional data. WT, n = 11; 1KO, n = 7; 1 Δ het, n = 7; 1 Δ hom, n = 10; 3KO, n = 5; 1+3KO, n = 5; 2KO, n = 3; WT3V5, n = 6; 1 Δ hom3V5, n = 6.

(D) Immunodetection of recombinant APOLs (0.5 μ g/mL) association with various lipids spotted on membrane strips. LPA, lysophosphatidic acid; LPC, lysophosphocholine; PI, phosphatidylinositol; PE, phosphatidylethanolamine; PC, phosphatidylcholine; S1p, sphingosine-1-phosphate; PA, phosphatidic acid; PS, phosphatidylserine; TG, triglyceride; DAG, diacylglycerol; PG, phosphatidylglycerol; CL, cardiolipin; Chol, cholesterol; SM, sphingomyelin. Blank, no lipid.

(E) Distribution of APOLs in cellular extracts from poly(I:C)-treated APOL3FLAG or APOL1 Δ het podocytes, fractionated as indicated. Anti-FLAG antibodies were used to detect APOL3. Calnexin and Golgin97 are representative ER transmembrane and peripheral *trans*-Golgi membrane markers, which become soluble with, respectively, 0.1% NP-40 (N) and carbonate pH 10 (C). The loading of “s” lanes corresponds to half that of “p” lanes.

(F) Distribution of APOLs in phosphatidylcholine liposomes containing or not containing 10% PI(4)P, following centrifugation at 10,000 \times g. S, supernatant; p, pellet; equal amounts of initial material.

naturally occurring APOL1 variants G1 and G2 contain mutations in the C-terminal LZ, which affect the LZ structure and binding of SRA and thus escape SRA-mediated neutralization (Genovese et al., 2010; Sharma et al., 2016). Presumably due to their ability to kill *T. b. rhodesiense* following SRA escape, these APOL1 variants are frequently found in African populations (Genovese et al., 2010). Unfortunately, the G1 and G2 variants also cause kidney disease (KD) through an unclear mechanism involving perturbation of podocyte vesicular traffic (Genovese et al.,

2010; Beckerman et al., 2017; Madhavan et al., 2017). Although the secreted fraction of the APOL1 variants was presented as responsible for the disease (Hayek et al., 2017), the variants present intracellularly must be involved in podocyte dysfunction, because circulating APOL1 levels do not correlate with the disease and because poor kidney allograft outcomes are associated with the APOL1 genotype of the transplanted kidney, but not of the recipient patient (Beckerman and Susztak, 2018; Madhavan et al., 2017). Since some APOL1 transcripts encode

isoforms that cannot be secreted (Cheatham et al., 2018), at least a fraction of intracellular APOL1 could exert a function in the cytosol rather than within the secretory pathway.

Despite the clear involvement of APOL1 G1 and G2 in KD, individuals lacking APOL1 due to mutations in both *APOL1* alleles (Vanhollebeke et al., 2006) appear to be healthy (Johnstone et al., 2012). Therefore, KD must result from negative effects of the APOL1 variants rather than APOL1 inactivation. In accordance with this conclusion, mice, which do not have the APOL1 gene, exhibit KD following transgenic expression of human APOL1 C-terminal variants, and not wild-type (WT) APOL1 (Beckerman et al., 2017).

Thus far, apart from the role of secreted APOL1 in innate immunity against African trypanosomes, the function of APOLs is unknown. However, roles in the defense against pathogens are likely (Smith and Malik, 2009; Vanhollebeke and Pays, 2006). The expression of different APOLs, particularly APOL1 and APOL3, is highly stimulated under inflammatory conditions, primarily those activating the Toll-like receptor 3 (TLR3) such as viral infection, which is mimicked *in vitro* by cell incubation with poly(I:C) (Nichols et al., 2015; Uzureau et al., 2016). Concordant with this observation, the risk of KD associated with the expression of C-terminal APOL1 variants is increased following viral infection (Kasembeli et al., 2015; Kopp et al., 2017).

Various molecular mechanisms have been proposed to explain the role of APOL1 C-terminal variants in podocyte dysfunction (Beckerman et al., 2017; Bruggeman et al., 2016; Cheng et al., 2015; Chun et al., 2019; Fu et al., 2017; Granado et al., 2017; Hayek et al., 2017; Jha et al., 2019; Kruzel-Davila et al., 2017; Kumar et al., 2019; Lan et al., 2014; Lee et al., 2018; Madhavan et al., 2017; Mikulak et al., 2016; Okamoto et al., 2018; Olabisi et al., 2016; O'Toole et al., 2018; Ryu et al., 2019; Wen et al., 2018; Zhang et al., 2018), but the heterogeneous nature of these mechanisms, together with drawbacks linked to non-specific toxicity due to APOL1 overexpression (O'Toole et al., 2018), suggested that the fundamental explanation remained undiscovered. Therefore, we undertook a detailed analysis of several human podocyte cell lines whose genomes were edited for the alteration of APOL1 and APOL3 genes, deliberately avoiding strategies of ectopic APOL expression. This resulted in the identification of a function of APOLs in the regulation of PI(4)P synthesis by PI4KB, hence in the control of actomyosin activity, which may explain the KD association of APOL1 G1 and G2.

RESULTS

APOL1 and APOL3 are Poly(I:C)-Induced Proteins Partially Associated with Endoplasmic Reticulum (ER) and Golgi Membranes

Incubation of podocytes with poly(I:C) strongly increased APOL1 and APOL3 expression (Figure 1B) and triggered cell death (WT lanes in Figures 1C, S1A, and S1B). In contrast, poly(I:C) only weakly increased APOL2 expression (Figure 1B).

APOL1 and APOL3 shared intranuclear and perinuclear distributions, the latter involving important co-localization with ER and *trans*-Golgi markers (Figures S2A–S2C). APOL3 co-localization with the Golgi was higher than that of APOL1, but this difference

was erased by poly(I:C) (Figure S2C). Like APOL1, APOL3 and APOL1 C-terminal variants exhibited *in vitro* binding to anionic phospholipids, particularly phosphatidic acid, cardiolipin, and several phosphoinositides (Figure 1D). In fractionated cellular extracts, the APOL1 and APOL3 distribution resembled more that of ER transmembrane calnexin than *trans*-Golgi membrane-associated Golgin97, also with a minor cytosolic fraction (Figure 1E). Finally, both APOLs exhibited increased binding to liposomes that contained PI(4)P (Figure 1F).

We conclude that in podocytes, APOL1 and APOL3 are poly(I:C)-induced phosphoinositide-binding proteins associating with ER and Golgi membranes.

Either APOL1 C-Terminal Helix Truncation or APOL3KO Induces Actomyosin Reorganization

We used CRISPR-Cas9-mediated gene targeting to generate different clones of APOL1KO, APOL3KO, and APOL1+3KO podocytes, together with clones encoding a C-terminally truncated APOL1 (APOL1 Δ , ending at V353, 36 kDa), either in only one allele (APOL1 Δ het) or both (APOL1 Δ hom) (Figures 1A, 1B, and S3). We also generated APOL2KO cells as controls. Whole-genome sequencing of representative clones did not reveal significant off-target editing (Table S1). In addition, given that all of the anti-APOL3 antibodies tested exhibited a non-specific interaction (Figure 1B, APOL3 top band), to enable specific APOL3 analysis, we used CRISPR-Cas9 genome editing to generate podocyte cell lines expressing the V5 or TriFLAG tag in C-terminal fusion with endogenous APOL3.

APOL1 Δ shared the cellular fractionation pattern of APOL1 (Figure 1E). Furthermore, synthesis of APOL1 Δ and tagged APOL3 was still stimulated by poly(I:C), suggesting no significant alteration of gene expression due to *APOL* editing (Figure 1B).

In accordance with the involvement of APOLs in apoptosis triggered by TLR3 activation (Uzureau et al., 2016), poly(I:C)-induced cell death was reduced in both APOL1KO and APOL3KO podocytes (Figures 1C, S1A, and S1B). In APOL1 Δ cell lines, poly(I:C)-induced cell death almost disappeared, suggesting that APOL1 Δ inhibits the death-promoting activity of APOLs (Figures 1C, S1A, and S1B). In contrast, APOL2 was not significantly involved in poly(I:C)-induced cell death (Figure 1C). Finally, cells with *in situ*-tagged APOL3 behaved like WT podocytes, suggesting no influence of the tag on APOL3 function (Figure 1C).

We compared the observable cytological characteristics of the different cell lines. The phenotypes of APOL1 Δ and APOL3KO cells, but not of APOL1KO, APOL1+3KO, and APOL2KO cells, were characterized by changes in cell surface area and perimeter (Figures 2A, S1C, and S1D), decrease in cellular adherence to fibronectin (Figure 2B), increase in motility linked to larger focal adhesion size (Figures 2C and S4A), and loss of actin stress fibers associated with tropomyosin accumulation in the perinuclear region (Figure 2D). In APOL1 Δ cells, add-back APOL1 expression reversed the increase in motility, confirming that the phenotypic differences resulted from APOL1 alteration (Figures 2C and S4A). The APOL1 Δ -APOL3KO phenotype also included the surface area reduction of mitochondria (Figure 2E), Golgi apparatus (Figure 2F), and ER tubules (Figure S4B), suggestive of increased membrane fission.




Figure 2. APOL1 Δ Expression or APOL3KO Triggers Actomyosin Reorganization

(A) Cellular area and perimeter of the different podocyte cell lines. WT, n = 96; 1KO, n = 84; 1 Δ hom, n = 127; 3KO, n = 98; 1+3KO, n = 84; 2KO, n = 61. (B) Cellular adhesion of the different podocyte cell lines on fibronectin-coated plates. WT, n = 12; 1KO, n = 8; 1 Δ hom, n = 12; 3KO, n = 12; 1+3KO, n = 12; 2KO, n = 10. (C) Cellular motility and adhesion foci size of the different podocyte cell lines as determined by vinculin immunostaining. Speed panel: WT, n = 240; 1KO, n = 148; 1 Δ hom, n = 223; 3KO, n = 191; 1+3KO, n = 86; 2KO, n = 75; 1 Δ +adb, n = 99. Focal adhesion size panel: WT, n = 970; 1KO, n = 1,628; 1 Δ hom, n = 2,006; 3KO, n = 1,706. (D) Actin and tropomyosin immunofluorescence confocal microscopy of representative samples of the different podocyte cell lines (n = 3). (E) Mitochondria size morphology of the different podocyte cell lines as determined by MicroP software analysis. WT, n = 24; 1KO, n = 24; 1 Δ hom, n = 12; 3KO, n = 22; 1+3KO, n = 9. (F) Golgi extent of the different podocyte cell lines as determined by Golgin97 staining. WT, n = 51; 1KO, n = 34; 1 Δ hom, n = 66; 3KO, n = 72; 1+3KO, n = 51. All results are expressed as means \pm SDs. All scale bars, 20 μm .

Accordingly, in these podocytes, a larger fraction of the ER and ER-linked inverted formin 2 (INF2), which recruits actomyosin on ER for organelle fission (Chakrabarti et al., 2018; Curchoe and Manor, 2017; Hatch et al., 2014), was associated with the non-muscular myosin NM2A heavy-chain MYH9 (Figure S4C).

Thus, in addition to the inhibition of APOL involvement in poly(I:C)-induced cell death, APOL1 Δ expression or APOL3KO induced similar podocyte actomyosin reorganization for reduced cellular adherence, increased motility, and increased organelle fission.

Either APOL1 C-Terminal Helix Truncation or APOL3KO Inhibits PI(4)P Synthesis at the Golgi

Several actomyosin components, such as MYH9 and gelsolin, share the ability of APOL1 to bind phosphoinositides (Liu

et al., 2016; Nag et al., 2013). Therefore, we investigated whether the effects of APOLs on actomyosin organization may be related to their ability to bind these phospholipids. APOL1 and APOL3 exhibited extensive co-localization with the major Golgi phosphoinositide PI(4)P (Figure 3A). In APOL1 Δ and APOL3KO cells, but not in the APOL1KO and APOL1+3KO cells, the PI(4)P content was strongly reduced with respect to WT cells (Figures 3B and S5A), and the Golgi exhibited the typical condensation observed following experimental PI(4)P depletion (Dippold et al., 2009) (Figures 2F and S5B). APOL1 and APOL3 appeared to exert, respectively, negative and positive effects on PI(4)P content, since their respective absence was associated with a slight increase or a strong decrease in PI(4)P levels (Figures 3B, S5A, and S5B). The overexpression of APOLs induced by poly(I:C)




Figure 3. APOL1 and APOL3 Control PI(4)P Synthesis

(A) Co-localization of APOL1 and APOL3 with PI(4)P. APOL1, n = 22; APOL3V5, n = 19.

(B) Relative content of PI(4)P and Golgi-associated PI(4)P in the different podocyte lines. Normalized PI(4)P panel: WT, n = 55; 1KO, n = 21; 1Δhom, n = 61; 3KO, n = 27; 1+3KO, n = 14; WT+poly(I:C), n = 15. GMP130/PI(4)P overlap panel: WT, n = 24; 1KO, n = 22; 1Δhom, n = 29; 3KO, n = 36; 1+3KO, n = 28; WT+poly(I:C), n = 15.

(C) Relative content of PI(4,5)P₂ in WT, APOL1Δ, and APOL3KO cells. WT, n = 17; 1Δhom, n = 15; 1KO, n = 14.

(D) Western blot analysis of total cellular extracts and PI4KB immunoprecipitates from various podocyte lines. Immunoprecipitates loading corresponds to 20- to 25-fold more cellular material than total extracts loading.

(E) PI(4)P synthesis by recombinant PI4KB (50 ng) with or without the addition of different recombinant proteins, expressed as percentage of activity without addition. The activity without PI substrate or without PI4KB (<0.1%) was subtracted.

(F) Surface area comparison of *trans*-Golgi network and Golgi stacks between different podocytes lines, as determined by transmission electron microscopy (bars, 500 nm). The yellow stars label vesicles of the *trans*-Golgi network. WT, n = 39; 1Δhom, n = 17.

All scale bars, 20 μm. Quantitative measurements are expressed as means ± SDs.

only slightly affected PI(4)P (Figure 3B). In contrast to PI(4)P at the Golgi, PI(4,5)P₂ levels at the plasma membrane were similar between cell lines (Figure 3C), suggesting that the cellular phenotype was specifically related to Golgi PI(4)P.

As shown in Figure 3D, the reduction of PI(4)P was not due to the reduced expression of PI4KB or NCS-1, a PI4KB activator (de Barry et al., 2006; Haynes et al., 2005; Mikhaylova et al., 2009; Taverna et al., 2002; Zhao et al., 2001). Likewise, it was not explained by the increased expression or delocalization of the PI(4)P phosphatase SAC-1 (Del Bel and Brill, 2018) to the *trans*-Golgi (Figures 3D and S5C). Thus, it likely resulted from PI4KB inactivation. In PI4KB immunoprecipitates,

PI4KB activity was too low to reliably detect differences between cell lines, possibly due to inefficient NCS-1 co-immunoprecipitation with PI4KB (Figure 3D). Under *in vitro* conditions, APOL3, but not NCS-1, triggered the Ca²⁺-dependent stimulation of PI4KB activity (Figure 3E). This stimulation also occurred with APOL1 or with APOL3+NCS-1, but at a lower level (Figure 3E). Thus, in APOL3KO and APOL1Δ cells, APOL3 absence or eventual APOL3 inactivation could account for the reduction in PI4KB activity.

In line with the relation between APOL3 and PI4KB activity, APOL3 was found to co-localize with PI4KB, together with NCS-1 and with the PI(4)P- and myosin-binding protein

GOLPH3 (Dippold et al., 2009) (Figure S5D). Moreover, in APOL1Δ podocytes, the co-localization of PI4KB, NCS-1, and GOLPH3 with APOL3 was reduced (Figure S5D), although PI4KB and NCS-1 remained closely associated (Figure S5D).

In accordance with the role of PI(4)P in secretion, the lowering of PI(4)P in APOL1Δ cells was associated with the surface area reduction of the *trans*-Golgi vesicular network and collapse of Golgi stacks (Figure 3F).

We conclude that besides the ability of APOLs to bind phosphoinositides, their activity is related to *in vivo* PI(4)P synthesis by PI4KB at the Golgi.

APOL1 Only Indirectly Associates with Actomyosin Components

We undertook a search for APOL1 partners that would participate in the APOL1 effects on actomyosin through the modulation of PI(4)P synthesis. The immunoprecipitation of APOL1 from NP-40 detergent-treated cellular extracts selectively pulled down several actomyosin components, particularly NM2A (heavy-chain MYH9, regulatory light-chain MYL9/12A, and essential light-chain MYL6), together with gelsolin and tropomyosin, but not actin (Figure S6). However, approaches aiming at identifying direct association with APOL1 did not reveal these components (see below). Thus, both APOL1 association with actomyosin components and effects on actomyosin organization could be indirect, possibly through phosphoinositide binding.

Alteration of the C-Terminal Helix Affects APOL1 Folding

To identify components directly interacting with APOL1, yeast two-hybrid (Y2H) screening was performed in a podocyte cDNA expression library (Figures S7A–S7C). This screen revealed frequent interactions between N- and C-terminal APOL1 sequences, the smallest interacting domains (SIDs) being, respectively, the 78–121 and 346–390 stretches (designated, respectively, SID1 and SID2; Figures S7C–S7E). APOL1 SID1 also interacted with the APOL2 and APOL3 C termini, which share extensive sequence similarity with SID2 (Figures S7C–S7E). The two SIDs exhibited a similar structure, with a hydrophobic cluster (HC) followed by a LZ (Figures 4A and S7E). More stringent conditions of Y2H screening still allowed interactions between SIDs and revealed that G2 mutations reduced this interaction (Figures S8A and S8B). The SID1 sequence was subsequently mutated to destroy the heptad repeat hydrophobicity in LZ1 (LZ1mut: L111Q/L115Q/L118Q). These mutations did not inactivate APOL1, since the LZ1mut mutant displayed conserved trypanolytic potential (Figure S8C), but they disrupted the interaction between SIDs (Figure S8D), revealing the role of LZs in this process.

Surface plasmon resonance (SPR) measurements confirmed the interaction between the SID1 and SID2 peptides (Figure 4B). Both HC and LZ sequences contributed to this interaction, since HC1 deletion (in the LZ1p peptide), LZ2 deletion (in the HC2p peptide), and LZ2 mutations (in the G1Cp–G2Cp peptides) affected the interaction (Figures 4B and 4C). The LZ1p peptide did not interact with HC2p (Figures 4B and 4C), supporting the

hypothesis that the interaction between SID1 and SID2 is driven by both HC1–HC2 and LZ1–LZ2 interactions.

Evidence that such interactions occur *in cis* within APOL1 was impossible to verify experimentally due to the aggregation of recombinant APOL1, which prevented analysis by either intramolecular fluorescence resonance energy transfer or double electron–electron resonance. However, during electrophoresis with SDS, APOL1Δ exhibited faster migration than expected from its size (34.4 kDa), a discrepancy that was not seen for WT APOL1 (Figure 4D). Since such a mobility shift in SDS results from increased hydrophobicity (Rath et al., 2009), LZ2 deletion appeared to increase APOL1 hydrophobicity. Accordingly, the removal of HC2 from APOL1Δ (in APOL1Δ1) restored the expected electrophoretic mobility (Figure 4D). The increased exposure of HC2 following LZ2 deletion suggested that LZ2 favors HC2 *cis*-interaction with HC1 in SID1. In the case of the G1 and G2 variants, no electrophoretic mobility shift could be detected (Figure 4D), but staining of these proteins with Nile red also revealed increased hydrophobicity with respect to WT APOL1 (Figure 4E).

These observations suggested that WT APOL1 is folded through *cis*-interaction between SID1 and SID2 and that deletion or mutation of LZ2 disrupts APOL1 folding, increasing the exposure of HCs (Figure 4F).

Alteration of the C-Terminal Helix Increases APOL1 Interaction with APOL3

Y2H screening indicated that the N-terminal region of APOL1 can interact at low frequency with the C-terminal region of APOL3 (Figure S7D). SPR measurements confirmed that APOL1 SID1p interacts with the APOL3 sequence homologous to SID2 (A3Cp). This interaction exhibited lower affinity than that between APOL1 SIDs and was strongly dependent on HC1 (Figures 4B and 4C).

Using biolayer interferometry (BLI) measurements, only weak binding was observed between WT APOL1 and APOL3 (Figure 5A), but the binding increased when LZ2 was deleted (APOL1Δ) or distorted (G1 and G2), or when LZ1 was disrupted (LZ1mut) (Figure 5A). Thus, reducing the probability of interactions between SID1 and SID2 led to the increased binding of APOL1 to APOL3 (models in Figures 4F and 4G). This binding did not require Ca²⁺ (Figure 5A).

Gene co-expression using the pDUET system in *Escherichia coli* confirmed that APOL1 and APOL1 variants can interact with APOL3 (Figure 5B, top panel). As a control, neither WT APOL1 nor APOL1Δ interacted with tropomyosin.

Finally, in support of APOL1–APOL3 interaction *in vivo*, APOL1 was detected in FLAG immunoprecipitates from WT–APOL3–FLAG cells (Figure 5C).

We conclude that APOL1 can bind to APOL3 in a mechanism enhanced by the alteration of either LZ2 or LZ1.

Intracellular APOL1 Topology Is Compatible with APOL1–APOL3 Interaction

Since APOL1 and APOL3 are supposed to be on opposite faces of intracellular membranes due to the presence of the signal peptide in APOL1 only, the biological relevance of the interaction between these proteins was questionable. Therefore, we




Figure 4. SID1 Interactions with SID2 Inhibit HC Exposure in APOL1

(A) Sequences of the synthetic peptides used for SPR measurements (SID1p and LZ1p = APOL1 K73-K125 and L88-K125; SID2p, G1Cp, G2Cp = APOL1 G332-L392 from WT or variant sequences; A3Cp = APOL3 G265-L325). Violet and pink colors highlight residues defining the hydrophobic clusters (HC, violet) and leucine zippers (LZ, pink). Yellow and green colors, respectively, indicate the N-term tag used for coupling the peptides to the SPR chip and residues specific to G1 and G2 variants. In A3Cp, residues evoking the APOL1 G1 or G2 variants are shown in blue.

(B) SPR-determined binding parameters for the interactions of the SID1p and LZ1p peptides to various immobilized peptides.

(C) SPR sensorgrams of interactions between SID peptides.

(D) Electrophoretic mobility shift of APOL1 Δ . A1, Δ and $\Delta 1$ = APOL1 60–398, 60–353, and 60–342, respectively (expected sizes: 41.3, 34.4, and 32.2 kDa). The sequence of the APOL1 Δ band excised from the SDS-PAGE gel was determined by mass spectrometry to check its integrity (peptide coverage in yellow; oxidized methionines in green). The HC2 sequence is underlined, and the C terminus of APOL1 $\Delta 1$ is denoted by an arrow.

(E) Nile red staining of recombinant APOL1, G1, or G2 (1 μ M each). Fluorescence emitted by Nile red (0.01 μ M) was measured at 630 nm (fluorescence of APOL1 was set to 1). Error bars, SDs; n = 9.

(F) Model for the interactions between SIDs in APOL1. LZ2 with a star, mutant leucine zipper, exhibiting reduced interaction affinity with LZ1. K⁺ refers to channel activity (parentheses denote inactivation).

(G) Model for the interactions between APOL3 and NCS-1 (top) or APOL1 Δ +NCS-1 (bottom). The APOL3 sequences homologous to APOL1 HCs and LZs are indicated in italics. K⁺ refers to channel activity (parentheses denote inactivation).

investigated the topology of APOL1 by immunogold electron microscopy. Labeling with anti-APOL1 antibody revealed clusters of gold particles in the cytosol of WT cells (Figure S9A), and such particles were never seen in the cytosol of APOL1KO cells (data not shown). Part of this labeling was localized close to the mitochondrion (Figure S9A). No ER or Golgi membrane-associated APOL1 labeling was detected, suggesting that epitopes of membrane-inserted APOL1 are not accessible to the antibody under the immunogold conditions, which exclude treatment with detergents.

The presence of cytosolic APOL1 could be related to differential processing between intracellular and secreted APOL1, since the

apparent size of APOL1, as deduced from electrophoresis with SDS, differed between podocyte extracts and human serum (Figure S9B). The expression of APOL1 isoforms unable to be secreted (isoforms 2 and 3, respectively; NCBI: NP_663318.1 and NP_001130013.1) could account for this observation, since transcripts for these isoforms were detected in podocytes (Cheatham et al., 2018). In particular, transcripts for isoform 3 represented ~5% of total APOL1 transcripts (Figure S9C). A possible cleavage in isoform 3, resulting in an improbable signal peptide unlikely to allow membrane translocation (12 hydrophobic residues instead of 17 in WT APOL1), would confer the size observed for intracellular APOL1 (Figures S9D and S9E). In support of this




Figure 5. APOL1 C-Terminal Variation Influences APOL3 Binding to APOL1 and NCS-1

(A) BLI measurements of interaction between bound APOL3 and recombinant WT APOL1 or APOL1 variants, either in SID1 (LZ1mut) or SID2 (APOL1Δ, G1, G2) (n = 3).
 (B) Interactions between APOLs and APOL3 (top panel) or NCS-1 (bottom panel), as measured in the *E. coli* pDUET co-expression system. Nickel binding of S-tagged proteins reflects their association with His-tagged partners (highlighted within red frames). A1, Δ, and Δ1 = APOL1 60-398, 60-353, and 60-342, respectively; A3 = APOL3; 3N = APOL3+1% NP-40 instead of 1% CHAPS; M3 = APOL3 HC2-like mutant HCmut. These data are representative of at least 5 independent experiments.
 (C) Western blot analysis of APOL1, TriFLAG-tagged APOL3, and NCS-1 immunoprecipitates from podocytes. All of the extracts were treated with 1% CHAPS.
 (D) BLI measurements of interactions between bound NCS-1 and APOL3 under various calcium concentrations (n = 3).
 (E) BLI measurements of interactions between bound NCS-1 and various recombinant APOLs, either WT or variant in SID1 (LZ1mut) or SID2 (APOL1Δ, G1, G2), performed in the presence of 50 μM CaCl₂ (n = 3).
 (F) BLI measurements of interactions between bound NCS-1 and APOL3, in the presence or absence of either 1% NP-40 or 1% CHAPS (n = 3).
 (G) BLI measurements of interactions between bound NCS-1 and APOL3 or PI4KB, added sequentially as indicated (n = 3).
 (H) BLI measurements of interactions between bound NCS-1 and APOL3, either alone or mixed with different molar ratios of APOL1 (left panel) or APOL1Δ (right panel) (n = 3).

hypothesis, APOL1 isoform 3 lacks the exon 4 sequence, which is unlikely to be present in intracellular APOL1 since this sequence is strongly cytotoxic (Khatua et al., 2015).

The protein fractionation data presented in Figure 1E suggested that most intracellular APOL1 behaves like the transmembrane protein calnexin. Since the APOL1Δ intracellular distribution pattern mimicked that of APOL1 (Figure 1E), APOL1-Δ should be inserted into membranes like APOL1.

In conclusion, intracellular APOL1 is processed differently from the secreted fraction and could be encoded by isoform 3

transcripts. This APOL1 fraction could share the cytoplasmic localization of APOL3.

APOL3, but Not APOL1, Interacts with NCS-1, Promoting Association of NCS-1 with PI4KB

Y2H screening only detected infrequent interactions between the N- and C-terminal regions of APOL3 (Figure S10A), contrasting strikingly with the high frequency of such interactions in the case of APOL1. Thus, in the case of APOL3, internal SID1-SID2-like interactions are improbable. Accordingly, the APOL3

sequence homologous to APOL1 LZ1 exhibited a much lower coiled-coiling potential than that of APOL1 (Figure S10B). Y2H screening with full APOL3, inactivated by site-directed mutagenesis of the transmembrane hairpin loop to avoid toxicity (APOL3 null: L137Q/A138Q/P139S/G143S) (Fontaine et al., 2017), identified NCS-1 as a major interacting partner (Figure S10C). Such an interaction with NCS-1 was not observed for inactivated APOL1 or APOL1 Δ (null mutants: P198S/G202S/G203S) (Figures S8C and S8E).

Gene co-expression in the *E. coli* pDUET system confirmed both APOL3-NCS-1 interaction and the absence of APOL1-NCS-1 interaction (Figure 5B, bottom panel). APOL3 interaction with NCS-1 required the HC2-like sequence, as it was lost following HC mutagenesis (HCmut: I276Q/F277A/L280Q/V283Q/Y287Q) (Figure 5B, lane M3), which still conserved trypanolytic activity (Figure S8C). Binding of the APOL3 HC2-like sequence to NCS-1 was in keeping with the strong hydrophobic nature of peptide interactions with NCS-1 (Pandalaneni et al., 2015), which also explains the loss of APOL3-NCS-1 interaction occurring with the non-ionic detergent NP-40, but not with the ionic detergent CHAPS (Figure 5B, bottom panel, lane 3N). In accordance with these observations, NCS-1 and APOL3FLAG were found to be present in, respectively, FLAG and NCS-1 immunoprecipitates from CHAPS-treated extracts of APOL3FLAG podocytes (Figure 5C).

More detailed measurements of protein interactions by BLI revealed that the interaction of APOL3 with NCS-1 required Ca^{2+} , within concentrations found at the cytoplasmic periphery of ER membranes (1–100 μM) (Rüdiger et al., 2010; Figure 5D). Interaction of APOL3 with NCS-1 contrasted strikingly with the lack of APOL1-NCS-1 interaction (Figure 5E). The hydrophobic nature of the APOL3-NCS-1 interaction was confirmed by mutagenesis. Mutations altering either the APOL3 HC2-like sequence (HCmut) or the hydrophobic crevice surface of NCS-1 such as L89K or F85K (Pandalaneni et al., 2015) reduced the interaction (Figures S11A and S11B). Moreover, as expected from observations in *E. coli* (Figure 5B), the APOL3-NCS-1 interaction was abolished in NP-40, but not in CHAPS (Figure 5F). The interaction between APOL3 and NCS-1 exhibited high affinity ($K_d = 36.5 \pm 2.6$ nM; Figure S11C), comparable to that measured for interaction between the yeast PI4KB and NCS-1 homologs Pik1 and Frq1, which also involves hydrophobic bonds ($K_d \sim 100$ nM) (Huttner et al., 2003; Strahl et al., 2003, 2007). The APOL3-NCS-1 interaction occurred irrespective of NCS-1 N-myristoylation (Figures 5G, S11D, and S11E), contrasting with the requirement of N-myristoylation for the interaction of NCS-1 with PI4KB (Zhao et al., 2001). Remarkably, APOL3 increased the interaction of NCS-1, even non-myristoylated, with PI4KB (Figures 5G and S11E).

In summary, APOL3, but not APOL1, exhibited high affinity and Ca^{2+} -dependent interaction with NCS-1. This interaction occurred through hydrophobic contacts involving the APOL3 HC2-like sequence (Figure 4G) and promoted the association of NCS-1 with PI4KB.

APOL1 and APOL1 C-Terminal Variants Can Affect the Formation of the APOL3-NCS-1 Complex

We evaluated the effect of the interaction of APOL1 with APOL3 on the APOL3 association with NCS-1. When present in excess,

APOL1 reduced the interaction between APOL3 and NCS-1, but in contrast, APOL1 Δ contributed to the increase in the signal of NCS-1 binding (Figure 5H, left and right panels, respectively). Since APOL1 Δ did not bind to NCS-1 (Figure 5E), the latter observation indicated that a tripartite APOL1 Δ -APOL3-NCS-1 complex was formed (Figure 4G). However, neither APOL1 nor APOL1 Δ were able to bind to the preformed APOL3-NCS-1 complex (Figure S11F). The G2 and G1 variants behaved like APOL1 and not like APOL1 Δ , since they reduced the interaction between APOL3 and NCS-1 (Figure S11G).

We conclude that APOL1 and the G1 and G2 variants can hinder the association of APOL3 with NCS-1, whereas APOL1 Δ appeared to strengthen this association. Thus, the binding of APOL1 to APOL3 clearly interfered with APOL3-NCS-1 interactions, and this occurred in different ways, depending on the presence or absence of LZ2.

In Keeping with Its Association with NCS-1, APOL3 Exhibits K^+ Channel Activity

NCS-1 is known to interact with cation channels (Guo et al., 2002; Schlecker et al., 2006). Given its interaction with NCS-1 and its trypanolytic potential (Fontaine et al., 2017), APOL3 was expected to be an ion channel. In planar lipid bilayers at neutral pH, APOL3 generated voltage-independent K^+ -selective channels (Figure 6A). APOL3 differed from APOL1 since the latter required acidic pH for membrane insertion and exhibited voltage-dependent channel activity (Fontaine et al., 2017; Pérez-Morga et al., 2005; Thomson and Finkelstein, 2015). APOL3 channel activity was unaffected by the presence of PI(4)P (data not shown).

Given the topology of these channels in intracellular membranes, both APOL3 and APOL1 could similarly drive cytoplasmic K^+ influx into the ER and/or Golgi (Figure 6B).

APOL1 and APOL1 Δ Inhibit *In Vitro* Channel Activity of the APOL3-NCS-1 Complex

At neutral pH, APOL1 or APOL1 Δ cannot insert into membranes, and even at low pH, APOL1 Δ is inactive (Thomson and Finkelstein, 2015). This allowed us to study the effects of APOL1 or APOL1 Δ on APOL3 activity. NCS-1, APOL1, or APOL1 Δ did not inhibit APOL3 channel activity (Figure 6C). However, if NCS-1 was added after APOL1 or APOL1 Δ pre-incubation with APOL3, no longer could channel activity be recorded, provided Ca^{2+} was present (Figure 6C). Thus, Ca^{2+} -independent APOL1 or APOL1 Δ interaction with APOL3 appeared to inhibit the channel activity of the Ca^{2+} -dependent APOL3-NCS-1 complex (Figure 4G).

APOL1 and APOL3 Influence Intracellular Ca^{2+} Levels

APOL1 and APOL3 K^+ channel activities could serve as the ion counter-current for Ca^{2+} efflux by the ER-linked and NCS-1-activated inositol 1,4,5-trisphosphate receptor (IP3R) (Schlecker et al., 2006), or as the factors increasing Ca^{2+} uptake as observed with other low conductance K^+ channels (Kuom et al., 2012, 2015). Therefore, we investigated the effect of APOL3 channel activity on Ca^{2+} release or uptake. IP3R-mediated Ca^{2+} release provoked by the extracellular agonist ATP occurred in all cell lines, with overall similar characteristics (Figure 6D). However, the Golgi Ca^{2+}




Figure 6. APOL3 Exhibits K⁺ Channel Activity Influencing Intracellular Ca²⁺ Levels

(A) APOL3 channel activity in planar soy lipid membranes (n = 5).

(B) Model of APOL-mediated ion currents in the podocyte ER and Golgi membranes.

(C) Effects of APOL1 or APOL1Δ on APOL3 channel activity. APOL3, APOL1, and NCS-1 were added at 56, 59, and 109 pmol/mL (n values indicated in the table).

(D) Quantification of the peak of cytosolic Ca²⁺ increases in response to different ATP concentrations (n = 5). The values were normalized to the signal obtained using 100 μM ATP.

(E) Intracellular Ca²⁺ store contents. In the top panels, each curve is representative of one single experiment (calculated from three technical replicates). In the lower panels, data were quantified by calculating the area under the curve (AUC) normalized versus the WT cell line (black line). In the dot plots, each cell line is represented with a different color and each independent experiment is represented with a different symbol (left panel, n = 9; center and right panels, n = 7). Data belonging to the same experiment (e.g., 96-well plate) are indicated with the same symbol.

content was significantly reduced in APOL1Δ and APOL1+3KO cells, and the ER Ca²⁺ content was increased in APOL3KO cells (Figures 6D and 6E). In the Golgi, APOL1 and APOL3 could exert redundant Ca²⁺-controlling activity so that either the loss of both APOLs in APOL1+3KO cells or the inactivation of both APOLs in APOL1Δ cells would be required to reduce the Ca²⁺ level. In the ER, the absence of APOL3 could promote APOL1-mediated Ca²⁺ uptake.

We conclude that both APOL1 and APOL3 contribute to increasing the level of Ca²⁺ in intracellular stores.

Urinary and Glomerular G1 or G2 Podocytes Exhibit an APOL1Δ or APOL3KO-like Phenotype

To relate our findings with KD, podocytes were obtained from the urine of a G2/G2 individual suffering from CKD stage 4

post-perinatal asphyxia (Figures S12A–S12D) and from the urine of G1/G2 patients suffering from focal segmental glomerulosclerosis (FSGS) or HIV-associated nephropathy (HIVAN) (Okamoto et al., 2018), and we compared their analysis with that of WT (G0/G0) controls. Urinary podocytes from the G2/G2 individual exhibited a mild APOL1Δ phenotype, regarding their surface area, motility, PI(4)P content, and Golgi morphology (Figures 7A–7D). Significantly, reduction of PI(4)P content coupled to Golgi condensation was also observed in podocyte cell lines established from the urine of the FSGS and HIVAN G1/G2 patients (Figures 7E and 7F). Furthermore, in kidney biopsies from G1/G1 and G2/G2 patients (Gaillard et al., 2018), the mean PI(4)P level of glomeruli was clearly reduced with respect to the levels of WT individuals (Figure 7G).




Figure 7. Urine and Glomerular G1 and G2 Podocytes Exhibit an APOL1 Δ or APOL3KO-like Phenotype

(A) Surface and perimeter measurements of urine APOL1 WT (Ur Ctrl) and G2/G2 podocytes from an individual with stage 4 CKD. Ur Ctrl, n = 132; G2, n = 120.
 (B) Cellular motility of podocytes described in (A). Ur Ctrl, n = 192; G2, n = 186.
 (C) PI(4)P level of podocytes described in (A). Ur Ctrl, n = 77; G2, n = 71.
 (D) Size of Golgi stacks in podocytes described in (A), as determined by transmission electron microscopy (TEM) analysis. Ur Ctrl, n = 49; G2, n = 50.
 (E) PI(4)P level in urine APOL1 G0/G0 and G1/G2 podocytes from FSGS or HIVAN disease patients. G0, n = 31; FSGS, n = 30; HIVAN, n = 41.
 (F) Golgi extent in urine APOL1 G0/G0 and G1/G2 podocytes from FSGS or HIVAN disease patients, as determined by Golgin97 staining. G0, n = 32; FSGS, n = 32; HIVAN, n = 34.
 (G) PI(4)P level in glomeruli from biopsies from G0/G0, G1/G1, or G2/G2 transplanted kidneys. Glomeruli (G) and control regions (Ctrl) were analyzed for immunostaining with anti-PI(4)P antibodies. In the graph, the different-colored dots identify different donors. G0, n = 37; G1, n = 94; G2, n = 19.
 All of the quantitative results are expressed as means \pm SDs.

We conclude that the disease phenotype linked to the expression of C-terminal APOL1 variants is related to the reduction of PI(4)P at the Golgi.

DISCUSSION

We report that in kidney podocytes, either alteration of the C-terminal helix (LZ2) of APOL1 or deletion of APOL3 trigger reduction of PI(4)P synthesis at the Golgi, concomitant with actomyosin reorganization increasing cellular motility and organelle fission. As observed with actomyosin mutations (Brown et al., 2010; Kaplan et al., 2000), such a reorganization is susceptible to induce KD through podocyte dysfunction. In support of this view, in addition to the APOL1 variants G1 and G2, an APOL3 null variant allele was also found to exhibit significant association with KD (Skorecki et al., 2018).

We provide evidence that intracellular APOL1, which is present in the cytosol as a protein processed differently from secreted APOL1, can interact with APOL3 and that this interaction is increased by LZ2 deletion or mutations. We propose that in WT APOL1, *cis*-interaction between N- and C-terminal helices (LZ1 and LZ2) limits *trans*-interaction with APOL3, and that LZ2 alteration relieves this limitation (Figures 4F and 4G). Since LZ2 deletion in APOL1 Δ cells induced a phenotype strikingly similar to that of APOL3KO, the APOL1-APOL3 interaction resulting from LZ2 deletion should inactivate APOL3. Accordingly, we found that APOL1 inhibits APOL3 channel activity when NCS-1 is present.

We show that APOL3, but not APOL1, binds with high affinity to NCS-1. This binding occurred with Ca²⁺ concentrations found in the cytoplasm close to IP3R and NCS-1 (Rüdiger et al., 2010). *In vivo*, NCS-1 requires high Ca²⁺ levels to activate PI4KB

(de Barry et al., 2006; Mikhaylova et al., 2009). Accordingly, our data indicated that Ca^{2+} -dependent APOL3 binding to NCS-1 promotes NCS-1 interaction with PI4KB. *In vitro*, Ca^{2+} is not mandatory for PI4KB activation by N-myristoylated NCS-1 (Zhao et al., 2001), but we observed Ca^{2+} -dependent activation of PI4KB by APOL3. *In vitro* assays cannot mimic *in vivo* conditions for PI4KB activity, which involves recruitment of the kinase to *trans*-Golgi membranes. However, they revealed APOL3 as a possible PI4KB activator besides NCS-1. Since we did not find evidence for interaction between APOL3 and PI4KB unless NCS-1 was added, it is possible that despite its ability to directly activate PI4KB *in vitro*, *in vivo* APOL3 should interact with NCS-1 to activate PI4KB, explaining the Ca^{2+} dependence of this activation.

In keeping with their contrasting capability to interact with NCS-1, APOL1 and APOL3 appeared to differentially affect PI4KB *in vivo*, leading to, respectively, higher or lower PI(4)P levels when absent. *In vivo*, PI4KB activity is controlled by competition between inhibitory calneurons at low Ca^{2+} levels and stimulatory NCS-1 at high Ca^{2+} levels (Mikhaylova et al., 2009). Based on these observations, we propose a model for APOL involvement in PI4KB control (Figure S13A). APOL3 would activate PI4KB at high Ca^{2+} levels, dissociating the calneuron-PI4KB interaction because APOL3 promotes the association of NCS-1 with PI4KB. Therefore, in the absence of APOL3, such as in APOL3KO cells, PI4KB activity would be reduced even at high Ca^{2+} levels following conserved interaction with calneurons. In APOL1 Δ cells, increased APOL1 binding to APOL3 would interfere with the interaction of APOL3 and NCS-1, thus inactivating APOL3. In APOL1KO cells, the slight increase in the PI(4)P level could result from the loss of the ability of APOL1 to hinder APOL3-NCS-1 interaction. In APOL1+3KO cells, paradoxically, PI4KB appeared to be active despite the absence of APOL3. Such activity could result from the interaction of PI4KB and N-myristoylated NCS-1 (Zhao et al., 2001). Since the only difference between APOL3KO and APOL1+3KO cells is the absence of APOL1 in the latter case, it appears that in the absence of APOL3, APOL1 inhibits PI4KB activation by NCS-1. Since APOL3KO cells but not APOL1+3KO cells exhibited increased Ca^{2+} uptake in luminal ER stores, the absence of APOL3 alone may favor calneuron activity due to increased cytosolic Ca^{2+} depletion by APOL1. Moreover, calneuron-1 is also known to participate in Ca^{2+} storage in the ER (Kobuke et al., 2018).

We show that APOL1 indirectly associates with actomyosin components, particularly NM2A, gelsolin, and tropomyosin, and that editing of APOLs triggers actomyosin reorganization, while also affecting both organelle fission and Golgi structure. Organelle fission and Golgi-derived secretion involve annular membrane contraction by actin, which is dependent on non-muscle myosin 2A (NM2A) activity (Chakrabarti et al., 2018; Curchoe and Manor, 2017; Hatch et al., 2014, 2016; Miserey-Lenkei et al., 2017). The inhibitory effect of APOLs on organelle fission, also observed with APOL1 in trypanosomes (Vanwalleghem et al., 2015), could involve their strong binding to cardiophilin and phosphatidic acid, known to be key components recruiting the fission machinery to the mitochondrion and Golgi (Frohman, 2015; Kameoka et al., 2018; Pagliuso et al., 2016).

In addition, the effects of APOLs on PI(4)P levels are clearly expected to affect secretion, cellular traffic, and autophagy (Figure S13B), explaining the podocyte vesicular trafficking problems that are observed following the expression of APOL1 C-terminal variants either *in vitro* (Beckerman and Susztak, 2018) or in mice (Beckerman et al., 2017).

We propose that the G1 or G2 variants cause an APOL1 Δ -like phenotype because reduction of PI(4)P synthesis was observed in both urine podocytes and kidney glomeruli from G1 or G2 individuals. The G1 or G2 variants could result from a compromise between the requirement for the disruption of LZ2 interaction with the N-terminal LZ of SRA to resist *T. b. rhodesiense* and the necessity of preserving LZ2 interaction with APOL1 LZ1 to avoid actomyosin reorganization by unfolded APOL1. Maintaining a level of LZ2-LZ1 interaction may also be necessary for APOL1 channel activity, because in contrast to what occurs with the G1 or G2 mutations, either C-terminal truncation or SRA binding to this region completely inhibit this activity (Lecordier et al., 2009; Thomson and Finkelstein, 2015). While still allowing some LZ2 interaction with LZ1, the G1 or G2 mutations could destabilize the LZ2 structure enough to increase APOL1 binding to APOL3, preventing APOL3-mediated activation of PI4KB, and therefore progressively inducing podocyte dysfunctions responsible for CKD.

STAR★METHODS

Detailed methods are provided in the online version of this paper and include the following:

- KEY RESOURCES TABLE
- LEAD CONTACT AND MATERIALS AVAILABILITY
- EXPERIMENTAL MODEL AND SUBJECT DETAILS
 - Immortalized podocytes
 - Urinary G0 and G2 podocytes
 - Additional urinary podocytes
 - Renal biopsies
- METHOD DETAILS
 - Cultivation of immortalized podocytes
 - Generation of APOL-edited podocytes
 - *In situ* C-terminal tagged versions of APOL3
 - Genomic Analysis of the edited podocytes
 - APOL1 inducible cell line
 - Generation of G0 and G2 podocyte lines (Figure S12)
 - Analysis of renal biopsies
 - Apoptosis assays
 - Cell morphology analysis
 - Cell adhesion assays
 - Single cell motility assays
 - Mitochondria analysis
 - Transmission Electron Microscopy
 - Golgi size measurements
 - Western Blot analysis
 - Immunoprecipitation
 - Immunofluorescence
 - Immunogold labeling
 - Cellular fractionation
 - Mass spectrometry

- *In vitro* lipid binding assays
- Liposome association assays
- Y2H interaction assays
- pDUET assays
- N-myristoylated recombinant NCS-1
- SPR analysis
- BLI analysis
- Nile red-based hydrophobicity assay
- APOL1 variant quantification by qRT-PCR
- Trypanolysis assays
- PI4KB activity measurements
- Electrophysiology of APOL3
- Cytosolic Ca²⁺ measurement
- **QUANTIFICATION AND STATISTICAL ANALYSIS**
- **DATA AND CODE AVAILABILITY**

SUPPLEMENTAL INFORMATION

Supplemental Information can be found online at <https://doi.org/10.1016/j.celrep.2020.02.064>.

ACKNOWLEDGMENTS

We acknowledge M.A. Saleem (University of Bristol, UK), J.B. Kopp (NIH, USA), M. Deleu (University of Gembloux, Belgium), L. van den Heuvel (University of Leuven, Belgium), M.A. Elmonem (University of Leuven, Belgium and University of Cairo, Egypt), and V. Martens (University of Brussels, Belgium) for providing the original podocyte cell line, G0/G0 and G1/G2 urinary podocytes, PI(4)P-containing liposomes, and help in generating and cultivating podocyte lines. This work was supported by the European Research Council (ERC) grant 669007-APOLs (to E.P.), grant 1101614N from the Research Foundation Flanders (to B.C.), and grants J.0078.18 and J.0091.17 from the Belgian Fonds de la Recherche Scientifique (FRS) (to C.E. and D.P.-M., respectively). S.U. is Chargé de Recherche FRS, and F.H. is Directeur de Recherche FRS. A.R.R. is supported by a Télévie fellowship. The CMMI is supported by the European Regional Development Fund and the Walloon Region. Computational resources were provided by the Flemish Supercomputer Center at the University of Antwerp (CalcUA).

AUTHOR CONTRIBUTIONS

E.P. and S.U. conceived the work; S.U., L.L., P.U., D.H., J.H.G., F.H., P.E.M., F.O.A., A.R.R., R.M.L.R., T.L., M.V., P.T., M.D., and M.R. performed the experiments and/or the generation of cell lines or tissue samples; B.C. and S.D. analyzed the DNA of the different cell lines; S.U., C.L., S.K.M., E.L., G.B., C.E., D.P.-M., and E.P. supervised different aspects of the experimental plan; E.P. and S.U. wrote the paper.

DECLARATION OF INTERESTS

The authors declare no competing interests.

Received: September 27, 2019

Revised: January 17, 2020

Accepted: February 14, 2020

Published: March 17, 2020

SUPPORTING CITATIONS

The following references appear in the Supplemental Information: Billington et al. (2015); Bishé et al. (2012); Chen et al. (2016); Judith et al. (2019); Kam et al. (2000); Klima et al. (2016); Kuna and Field (2019); Rodrigues et al. (2016); Taft et al. (2013); Tan and Brill (2014); Tokuda et al. (2014); Tu et al. (2012).

REFERENCES

- Beckerman, P., and Susztak, K. (2018). APOL1: the balance imposed by infection, selection, and kidney disease. *Trends Mol. Med.* *24*, 682–695.
- Beckerman, P., Bi-Karchin, J., Park, A.S.D., Qiu, C., Dummer, P.D., Soomro, I., Boustany-Kari, C.M., Pullen, S.S., Miner, J.H., Hu, C.-A.A., et al. (2017). Transgenic expression of human APOL1 risk variants in podocytes induces kidney disease in mice. *Nat. Med.* *23*, 429–438.
- Billington, N., Beach, J.R., Heissler, S.M., Remmert, K., Guzik-Lendrum, S., Nagy, A., Takagi, Y., Shao, L., Li, D., Yang, Y., et al. (2015). Myosin 18A coassembles with nonmuscle myosin 2 to form mixed bipolar filaments. *Curr. Biol.* *25*, 942–948.
- Bishé, B., Syed, G.H., Field, S.J., and Siddiqui, A. (2012). Role of phosphatidylinositol 4-phosphate (PI4P) and its binding protein GOLPH3 in hepatitis C virus secretion. *J. Biol. Chem.* *287*, 27637–27647.
- Bittremieux, M., Gerasimenko, J.V., Schuermans, M., Luyten, T., Stapleton, E., Alzayady, K.J., De Smedt, H., Yule, D.I., Mikoshiba, K., Vangheluwe, P., et al. (2017). DPB162-AE, an inhibitor of store-operated Ca²⁺ entry, can deplete the endoplasmic reticulum Ca²⁺ store. *Cell Calcium* *62*, 60–70.
- Bolger, A.M., Lohse, M., and Usadel, B. (2014). Trimmomatic: a flexible trimmer for Illumina sequence data. *Bioinformatics* *30*, 2114–2120.
- Bolte, S., and Cordelières, F.P. (2006). A guided tour into subcellular colocalization analysis in light microscopy. *J. Microsc.* *224*, 213–232.
- Brown, E.J., Schlöndorff, J.S., Becker, D.J., Tsukaguchi, H., Tonna, S.J., Uscinski, A.L., Higgs, H.N., Henderson, J.M., and Pollak, M.R. (2010). Mutations in the formin gene INF2 cause focal segmental glomerulosclerosis. *Nat. Genet.* *42*, 72–76.
- Bruggeman, L.A., Wu, Z., Luo, L., Madhavan, S.M., Konieczkowski, M., Drawz, P.E., Thomas, D.B., Barisoni, L., Sedor, J.R., and O'Toole, J.F. (2016). APOL1-G0 or APOL1-G2 transgenic models develop preeclampsia but not kidney disease. *J. Am. Soc. Nephrol.* *27*, 3600–3610.
- Camacho Londoño, J., and Philipp, S.E. (2016). A reliable method for quantification of splice variants using RT-qPCR. *BMC Mol. Biol.* *17*, 8.
- Chakrabarti, R., Ji, W.-K., Stan, R.V., de Juan Sanz, J., Ryan, T.A., and Higgs, H.N. (2018). INF2-mediated actin polymerization at the ER stimulates mitochondrial calcium uptake, inner membrane constriction, and division. *J. Cell Biol.* *217*, 251–268.
- Cheatham, A.M., Davis, S.E., Khatua, A.K., and Popik, W. (2018). Blocking the 5' splice site of exon 4 by a morpholino oligomer triggers APOL1 protein isoform switch. *Sci. Rep.* *8*, 8739.
- Chen, P.-W., Jian, X., Heissler, S.M., Le, K., Luo, R., Jenkins, L.M., Nagy, A., Moss, J., Sellers, J.R., and Randazzo, P.A. (2016). The Arf GTPase-activating protein, ASAP1, binds nonmuscle myosin 2A to control remodeling of the actomyosin network. *J. Biol. Chem.* *291*, 7517–7526.
- Cheng, D., Weckerle, A., Yu, Y., Ma, L., Zhu, X., Murea, M., Freedman, B.I., Parks, J.S., and Shelness, G.S. (2015). Biogenesis and cytotoxicity of APOL1 renal risk variant proteins in hepatocytes and hepatoma cells. *J. Lipid Res.* *56*, 1583–1593.
- Chun, J., Zhang, J.-Y., Wilkins, M.S., Subramanian, B., Riella, C., Magraner, J.M., Alper, S.L., Friedman, D.J., and Pollak, M.R. (2019). Recruitment of APOL1 kidney disease risk variants to lipid droplets attenuates cell toxicity. *Proc. Natl. Acad. Sci. USA* *116*, 3712–3721.
- Cingolani, P., Platts, A., Wang, L., Coon, M., Nguyen, T., Wang, L., Land, S.J., Lu, X., and Ruden, D.M. (2012). A program for annotating and predicting the effects of single nucleotide polymorphisms. SnpEff: SNPs in the genome of *Drosophila melanogaster* strain w1118; iso-2; iso-3. *Fly (Austin)* *6*, 80–92.
- Curchoe, C.L., and Manor, U. (2017). Actin cytoskeleton-mediated constriction of membrane organelles via endoplasmic reticulum scaffolding. *ACS Biomater. Sci. Eng.* *3*, 2727–2732.
- de Barry, J., Janoshazi, A., Dupont, J.L., Procksch, O., Chasserot-Golaz, S., Jeromin, A., and Vitale, N. (2006). Functional implication of neuronal calcium sensor-1 and phosphoinositol 4-kinase-beta interaction in regulated exocytosis of PC12 cells. *J. Biol. Chem.* *281*, 18098–18111.

- Del Bel, L.M., and Brill, J.A. (2018). Sac1, a lipid phosphatase at the interface of vesicular and nonvesicular transport. *Traffic* 19, 301–318.
- Dippold, H.C., Ng, M.M., Farber-Katz, S.E., Lee, S.-K., Kerr, M.L., Peterman, M.C., Sim, R., Wiharto, P.A., Galbraith, K.A., Madhavarapu, S., et al. (2009). GOLPH3 bridges phosphatidylinositol-4-phosphate and actomyosin to stretch and shape the Golgi to promote budding. *Cell* 139, 337–351.
- Dunn, K.W., Kamocka, M.M., and McDonald, J.H. (2011). A practical guide to evaluating colocalization in biological microscopy. *Am. J. Physiol. Cell Physiol.* 300, C723–C742.
- Elong Edimo, W., Ghosh, S., Derua, R., Janssens, V., Waelkens, E., Vanderwinden, J.-M., Robe, P., and Erneux, C. (2016). SHIP2 controls plasma membrane PI(4,5)P2 thereby participating in the control of cell migration in 1321 N1 glioblastoma cells. *J. Cell Sci.* 129, 1101–1114.
- Fontaine, F., Lecordier, L., Vanwalleghem, G., Uzureau, P., Van Reet, N., Fontaine, M., Tebabi, P., Vanhollebeke, B., Büscher, P., Pérez-Morga, D., and Pays, E. (2017). APOLs with low pH dependence can kill all African trypanosomes. *Nat. Microbiol.* 2, 1500–1506.
- Frohman, M.A. (2015). Role of mitochondrial lipids in guiding fission and fusion. *J. Mol. Med. (Berl.)* 93, 263–269.
- Fu, Y., Zhu, J.Y., Richman, A., Zhang, Y., Xie, X., Das, J.R., Li, J., Ray, P.E., and Han, Z. (2017). APOL1-G1 in nephrocytes induces hypertrophy and accelerates cell death. *J. Am. Soc. Nephrol.* 28, 1106–1116.
- Gaillard, F., Gribouval, O., Courbebaisse, M., Fournier, C., Antignac, C., Legendre, C., and Servais, A. (2018). Comparison of postdonation kidney function between Caucasian donors and low-risk APOL1 genotype living kidney donors of African ancestry. *Transplantation* 102, e462–e463.
- Genovese, G., Friedman, D.J., Ross, M.D., Lecordier, L., Uzureau, P., Freedman, B.I., Bowden, D.W., Langefeld, C.D., Oleksyk, T.K., Uscinski Knob, A.L., et al. (2010). Association of trypanolytic ApoL1 variants with kidney disease in African Americans. *Science* 329, 841–845.
- Glück, J.M., Hoffmann, S., Koenig, B.W., and Willbold, D. (2010). Single vector system for efficient N-myristoylation of recombinant proteins in *E. coli*. *PLoS One* 5, e10081.
- Granado, D., Müller, D., Krausel, V., Kruzel-Davila, E., Schuberth, C., Eschborn, M., Wedlich-Söldner, R., Skorecki, K., Pavenstädt, H., Michgehl, U., and Weide, T. (2017). Intracellular APOL1 risk variants cause cytotoxicity accompanied by energy depletion. *J. Am. Soc. Nephrol.* 28, 3227–3238.
- Guo, W., Malin, S.A., Johns, D.C., Jeromin, A., and Nerbonne, J.M. (2002). Modulation of Kv4-encoded K(+) currents in the mammalian myocardium by neuronal calcium sensor-1. *J. Biol. Chem.* 277, 26436–26443.
- Hatch, A.L., Gurel, P.S., and Higgs, H.N. (2014). Novel roles for actin in mitochondrial fission. *J. Cell Sci.* 127, 4549–4560.
- Hatch, A.L., Ji, W.K., Merrill, R.A., Strack, S., and Higgs, H.N. (2016). Actin filaments as dynamic reservoirs for Drp1 recruitment. *Mol. Biol. Cell* 27, 3109–3121.
- Hayek, S.S., Koh, K.H., Grams, M.E., Wei, C., Ko, Y.-A., Li, J., Samelko, B., Lee, H., Dande, R.R., Lee, H.W., et al. (2017). A tripartite complex of suPAR, APOL1 risk variants and $\alpha_v\beta_3$ integrin on podocytes mediates chronic kidney disease. *Nat. Med.* 23, 945–953.
- Haynes, L.P., Thomas, G.M.H., and Burgoyne, R.D. (2005). Interaction of neuronal calcium sensor-1 and ADP-ribosylation factor 1 allows bidirectional control of phosphatidylinositol 4-kinase β and *trans*-Golgi network-plasma membrane traffic. *J. Biol. Chem.* 280, 6047–6054.
- Huttner, I.G., Strahl, T., Osawa, M., King, D.S., Ames, J.B., and Thorner, J. (2003). Molecular interactions of yeast frequenin (Frq1) with the phosphatidylinositol 4-kinase isoform, Ptk1. *J. Biol. Chem.* 278, 4862–4874.
- Ivanova, E.A., Arcolino, F.O., Elmonem, M.A., Rastaldi, M.P., Giardino, L., Cornelissen, E.M., van den Heuvel, L.P., and Levchenko, E.N. (2016). Cystinosis deficiency causes podocyte damage and loss associated with increased cell motility. *Kidney Int.* 89, 1037–1048.
- Jha, A., Kumar, V., Haque, S., Ayasolla, K., Saha, S., Lan, X., Malhotra, A., Saleem, M.A., Skorecki, K., and Singhal, P.C. (2019). Alterations in plasma membrane ion channel structures stimulate NLRP3 inflammasome activation in APOL1 risk milieu. *FEBS J.* <https://doi.org/10.1111/febs.15133>.
- Johnstone, D.B., Shegokar, V., Nihalani, D., Rathore, Y.S., Mallik, L., Ashish, Zare, V., Ikizler, H.O., Powar, R., and Holzman, L.B. (2012). APOL1 null alleles from a rural village in India do not correlate with glomerulosclerosis. *PLoS One* 7, e51546.
- Judith, D., Jefferies, H.B.J., Boeing, S., Frith, D., Snijders, A.P., and Tooze, S.A. (2019). ATG9A shapes the forming autophagosome through Arfaptin 2 and phosphatidylinositol 4-kinase III β . *J. Cell Biol.* 218, 1634–1652.
- Kam, J.L., Miura, K., Jackson, T.R., Gruschus, J., Roller, P., Stauffer, S., Clark, J., Aneja, R., and Randazzo, P.A. (2000). Phosphoinositide-dependent activation of the ADP-ribosylation factor GTPase-activating protein ASAP1. Evidence for the pleckstrin homology domain functioning as an allosteric site. *J. Biol. Chem.* 275, 9653–9663.
- Kameoka, S., Adachi, Y., Okamoto, K., Iijima, M., and Sesaki, H. (2018). Phosphatidic acid and cardiolipin coordinate mitochondrial dynamics. *Trends Cell Biol.* 28, 67–76.
- Kaplan, J.M., Kim, S.H., North, K.N., Renke, H., Correia, L.A., Tong, H.Q., Mathis, B.J., Rodríguez-Pérez, J.C., Allen, P.G., Beggs, A.H., and Pollak, M.R. (2000). Mutations in ACTN4, encoding alpha-actinin-4, cause familial focal segmental glomerulosclerosis. *Nat. Genet.* 24, 251–256.
- Kasembeli, A.N., Duarte, R., Ramsay, M., Mosiane, P., Dickens, C., Dix-Peek, T., Limou, S., Sezgin, E., Nelson, G.W., Fogo, A.B., et al. (2015). APOL1 risk variants are strongly associated with HIV-associated nephropathy in black South Africans. *J. Am. Soc. Nephrol.* 26, 2882–2890.
- Khatua, A.K., Cheatham, A.M., Kruzel, E.D., Singhal, P.C., Skorecki, K., and Popik, W. (2015). Exon 4-encoded sequence is a major determinant of cytotoxicity of apolipoprotein L1. *Am. J. Physiol. Cell Physiol.* 309, C22–C37.
- Klima, M., Tóth, D.J., Hexnerova, R., Baumlova, A., Chalupska, D., Tykvar, J., Rezačkova, L., Sengupta, N., Man, P., Dubankova, A., et al. (2016). Structural insights and in vitro reconstitution of membrane targeting and activation of human PI4KB by the ACBD3 protein. *Sci. Rep.* 6, 23641.
- Kobuke, K., Oki, K., Gomez-Sanchez, C.E., Gomez-Sanchez, E.P., Ohno, H., Itcho, K., Yoshii, Y., Yoneda, M., and Hattori, N. (2018). Calneuron 1 increased Ca²⁺ in the endoplasmic reticulum and aldosterone production in aldosterone-producing adenoma. *Hypertension* 71, 125–133.
- Kopp, J.B., Heymann, J., and Winkler, C.A. (2017). APOL1 renal risk variants: fertile soil for HIV-associated nephropathy. *Semin. Nephrol.* 37, 514–519.
- Kruzel-Davila, E., Shemer, R., Ofir, A., Bavli-Kertseli, I., Darlyuk-Saadon, I., Oren-Giladi, P., Wasser, W.G., Magen, D., Zaknoun, E., Schuldiner, M., et al. (2017). APOL1-mediated cell injury involves disruption of conserved trafficking processes. *J. Am. Soc. Nephrol.* 28, 1117–1130.
- Kumar, V., Paliwal, N., Ayasolla, K., Vashistha, H., Jha, A., Chandel, N., Chowdhary, S., Saleem, M.A., Malhotra, A., Chander, P.N., et al. (2019). Disruption of APOL1-miR193a axis induces disorganization of podocyte actin cytoskeleton. *Sci. Rep.* 9, 3582.
- Kuna, R.S., and Field, S.J. (2019). GOLPH3: a Golgi phosphatidylinositol(4) phosphate effector that directs vesicle trafficking and drives cancer. *J. Lipid Res.* 60, 269–275.
- Kuum, M., Veksler, V., Liiv, J., Ventura-Clapier, R., and Kaasik, A. (2012). Endoplasmic reticulum potassium-hydrogen exchanger and small conductance calcium-activated potassium channel activities are essential for ER calcium uptake in neurons and cardiomyocytes. *J. Cell Sci.* 125, 625–633.
- Kuum, M., Veksler, V., and Kaasik, A. (2015). Potassium fluxes across the endoplasmic reticulum and their role in endoplasmic reticulum calcium homeostasis. *Cell Calcium* 58, 79–85.
- Lan, X., Jhaveri, A., Cheng, K., Wen, H., Saleem, M.A., Mathieson, P.W., Mikulak, J., Aviram, S., Malhotra, A., Skorecki, K., and Singhal, P.C. (2014). APOL1 risk variants enhance podocyte necrosis through compromising lysosomal membrane permeability. *Am. J. Physiol. Renal Physiol.* 307, F326–F336.
- Lecordier, L., Vanhollebeke, B., Poelvoorde, P., Tebabi, P., Paturiaux-Hanocq, F., Andris, F., Lins, L., and Pays, E. (2009). C-terminal mutants of

- apolipoprotein L-I efficiently kill both *Trypanosoma brucei brucei* and *Trypanosoma brucei rhodesiense*. *PLoS Pathog.* 5, e1000685.
- Lecordier, L., Uzureau, P., Tebabi, P., Brauner, J., Benghiat, F.S., Vanhollebeke, B., and Pays, E. (2015). Adaptation of *Trypanosoma rhodesiense* to hypohaptoglobinaemic serum requires transcription of the APOL1 resistance gene in a RNA polymerase I locus. *Mol. Microbiol.* 97, 397–407.
- Lee, H., Roshanravan, H., Wang, Y., Okamoto, K., Ryu, J., Shrivastav, S., Qu, P., and Kopp, J.B. (2018). ApoL1 renal risk variants induce aberrant THP-1 monocyte differentiation and increase eicosanoid production via enhanced expression of cyclooxygenase-2. *Am. J. Physiol. Renal Physiol.* 315, F140–F150.
- Li, H. (2011). A statistical framework for SNP calling, mutation discovery, association mapping and population genetical parameter estimation from sequencing data. *Bioinformatics* 27, 2987–2993.
- Li, H. (2013). Aligning sequence reads, clone sequences and assembly contigs with BWA-MEM. *ArXiv*, 13033997v2 [q-bio.GN].
- Liu, X., Shu, S., Billington, N., Williamson, C.D., Yu, S., Brzeska, H., Donaldson, J.G., Sellers, J.R., and Korn, E.D. (2016). Mammalian nonmuscle myosin II binds to anionic phospholipids with concomitant dissociation of the regulatory light chain. *J. Biol. Chem.* 291, 24828–24837.
- Madhavan, S.M., O'Toole, J.F., Konieczkowski, M., Barisoni, L., Thomas, D.B., Ganesan, S., Bruggeman, L.A., Buck, M., and Sedor, J.R. (2017). APOL1 variants change C-terminal conformational dynamics and binding to SNARE protein VAMP8. *JCI Insight* 2, e92581.
- Meijering, E., Dzyubachyk, O., and Smal, I. (2012). Methods for cell and particle tracking. *Methods Enzymol.* 504, 183–200.
- Mikhaylova, M., Reddy, P.P., Munsch, T., Landgraf, P., Suman, S.K., Smalla, K.-H., Gundelfinger, E.D., Sharma, Y., and Kreutz, M.R. (2009). Calneurons provide a calcium threshold for trans-Golgi network to plasma membrane trafficking. *Proc. Natl. Acad. Sci. USA* 106, 9093–9098.
- Mikulak, J., Oriolo, F., Portale, F., Tentorio, P., Lan, X., Saleem, M.A., Skorecki, K., Singhal, P.C., and Mavilio, D. (2016). Impact of APOL1 polymorphism and IL-1 β priming in the entry and persistence of HIV-1 in human podocytes. *Retirology* 13, 63.
- Miserey-Lenkei, S., Bousquet, H., Pylypenko, O., Bardin, S., Dimitrov, A., Bressanelli, G., Bonifay, R., Fraissier, V., Guillou, C., Bougeret, C., et al. (2017). Coupling fission and exit of RAB6 vesicles at Golgi hotspots through kinesin-myosin interactions. *Nat. Commun.* 8, 1254.
- Mlayeh, L., Chatkaew, S., Léonetti, M., and Homblé, F. (2010). Modulation of plant mitochondrial VDAC by phytosterols. *Biophys. J.* 99, 2097–2106.
- Nag, S., Larsson, M., Robinson, R.C., and Burtnick, L.D. (2013). Gelsolin: the tail of a molecular gymnast. *Cytoskeleton (Hoboken)* 70, 360–384.
- Nichols, B., Jog, P., Lee, J.H., Blackler, D., Wilmot, M., D'Agati, V., Markowitz, G., Kopp, J.B., Alper, S.L., Pollak, M.R., and Friedman, D.J. (2015). Innate immunity pathways regulate the nephropathy gene Apolipoprotein L1. *Kidney Int.* 87, 332–342.
- O'Toole, J.F., Schilling, W., Kunze, D., Madhavan, S.M., Konieczkowski, M., Gu, Y., Luo, L., Wu, Z., Bruggeman, L.A., and Sedor, J.R. (2018). ApoL1 overexpression drives variant-independent cytotoxicity. *J. Am. Soc. Nephrol.* 29, 869–879.
- Okamoto, K., Rausch, J.W., Wakashin, H., Fu, Y., Chung, J.-Y., Dummer, P.D., Shin, M.K., Chandra, P., Suzuki, K., Shrivastav, S., et al. (2018). APOL1 risk allele RNA contributes to renal toxicity by activating protein kinase R. *Commun Biol* 1, 188.
- Olabisi, O.A., Zhang, J.-Y., VerPlank, L., Zahler, N., DiBartolo, S., 3rd, Heneghan, J.F., Schlöndorff, J.S., Suh, J.H., Yan, P., Alper, S.L., et al. (2016). APOL1 kidney disease risk variants cause cytotoxicity by depleting cellular potassium and inducing stress-activated protein kinases. *Proc. Natl. Acad. Sci. USA* 113, 830–837.
- Pagliuso, A., Valente, C., Giordano, L.L., Filograna, A., Li, G., Circolo, D., Turacchio, G., Marzullo, V.M., Mandrich, L., Zhukovsky, M.A., et al. (2016). Golgi membrane fission requires the CtBP1-S/BARS-induced activation of lysophosphatidic acid acyltransferase δ . *Nat. Commun.* 7, 12148.
- Pandalaneni, S., Karupiah, V., Saleem, M., Haynes, L.P., Burgoyne, R.D., Mayans, O., Derrick, J.P., and Lian, L.-Y. (2015). Neuronal Calcium Sensor-1 binds the D2 dopamine receptor and G-protein-coupled receptor kinase 1 (GRK1) peptides using different modes of interactions. *J. Biol. Chem.* 290, 18744–18756.
- Pays, E., Vanhollebeke, B., Uzureau, P., Lecordier, L., and Pérez-Morga, D. (2014). The molecular arms race between African trypanosomes and humans. *Nat. Rev. Microbiol.* 12, 575–584.
- Peng, J.-Y., Lin, C.-C., Chen, Y.-J., Kao, L.-S., Liu, Y.-C., Chou, C.-C., Huang, Y.-H., Chang, F.-R., Wu, Y.-C., Tsai, Y.-S., and Hsu, C.N. (2011). Automatic morphological subtyping reveals new roles of caspases in mitochondrial dynamics. *PLoS Comput. Biol.* 7, e1002212.
- Pérez-Morga, D., Vanhollebeke, B., Paturiaux-Hanocq, F., Nolan, D.P., Lins, L., Homblé, F., Vanhamme, L., Tebabi, P., Pays, A., Poelvoorde, P., et al. (2005). Apolipoprotein L-I promotes trypanosome lysis by forming pores in lysosomal membranes. *Science* 309, 469–472.
- Price, H.P., Hodgkinson, M.R., Wright, M.H., Tate, E.W., Smith, B.A., Carrington, M., Stark, M., and Smith, D.F. (2012). A role for the vesicle-associated tubulin binding protein ARL6 (BBS3) in flagellum extension in *Trypanosoma brucei*. *Biochim. Biophys. Acta* 1823, 1178–1191.
- Ran, F.A., Hsu, P.D., Wright, J., Agarwala, V., Scott, D.A., and Zhang, F. (2013). Genome engineering using the CRISPR-Cas9 system. *Nat. Protoc.* 8, 2281–2308.
- Rath, A., Glibowicka, M., Nadeau, V.G., Chen, G., and Deber, C.M. (2009). Detergent binding explains anomalous SDS-PAGE migration of membrane proteins. *Proc. Natl. Acad. Sci. USA* 106, 1760–1765.
- Rodrigues, F.F., Shao, W., and Harris, T.J.C. (2016). The Arf GAP Asap promotes Arf1 function at the Golgi for cleavage furrow biosynthesis in *Drosophila*. *Mol. Biol. Cell* 27, 3143–3155.
- Rüdiger, S., Nagaiah, Ch., Warnecke, G., and Shuai, J.W. (2010). Calcium domains around single and clustered IP3 receptors and their modulation by buffers. *Biophys. J.* 99, 3–12.
- Ryu, J.-H., Ge, M., Merscher, S., Rosenberg, A.Z., Desante, M., Roshanravan, H., Okamoto, K., Shin, M.K., Hoek, M., Fornoni, A., and Kopp, J.B. (2019). APOL1 renal risk variants promote cholesterol accumulation in tissues and cultured macrophages from APOL1 transgenic mice. *PLoS One* 14, e0211559.
- Saleem, M.A., O'Hare, M.J., Reiser, J., Coward, R.J., Inward, C.D., Farren, T., Xing, C.Y., Ni, L., Mathieson, P.W., and Mundel, P. (2002). A conditionally immortalized human podocyte cell line demonstrating nephrin and podocin expression. *J. Am. Soc. Nephrol.* 13, 630–638.
- Schlecker, C., Boehmerle, W., Jeromin, A., DeGray, B., Varshney, A., Sharma, Y., Szigeti-Buck, K., and Ehrlich, B.E. (2006). Neuronal calcium sensor-1 enhancement of InsP3 receptor activity is inhibited by therapeutic levels of lithium. *J. Clin. Invest.* 116, 1668–1674.
- Schoenmakers, T.J., Visser, G.J., Flik, G., and Theuvsen, A.P. (1992). CHELATOR: an improved method for computing metal ion concentrations in physiological solutions. *Biotechniques* 12, 870–874, 876–879.
- Sharma, A.K., Friedman, D.J., Pollak, M.R., and Alper, S.L. (2016). Structural characterization of the C-terminal coiled-coil domains of wild-type and kidney disease-associated mutants of apolipoprotein L1. *FEBS J.* 283, 1846–1862.
- Sibley, L.D., Niesman, I.R., Parmley, S.F., and Cesbron-Delauw, M.F. (1995). Regulated secretion of multi-lamellar vesicles leads to formation of a tubulo-vesicular network in host-cell vacuoles occupied by *Toxoplasma gondii*. *J. Cell Sci.* 108, 1669–1677.
- Skorecki, K.L., Lee, J.H., Langefeld, C.D., Rosset, S., Tzur, S., Wasser, W.G., Shemer, R., Hawkins, G.A., Divers, J., Parekh, R.S., et al. (2018). A null variant in the apolipoprotein L3 gene is associated with non-diabetic nephropathy. *Nephrol. Dial. Transplant.* 33, 323–330.
- Smith, E.E., and Malik, H.S. (2009). The apolipoprotein L family of programmed cell death and immunity genes rapidly evolved in primates at discrete sites of host-pathogen interactions. *Genome Res.* 19, 850–858.
- Strahl, T., Grafelmann, B., Dannenberg, J., Thörner, J., and Pongs, O. (2003). Conservation of regulatory function in calcium-binding proteins: human

- frequenin (neuronal calcium sensor-1) associates productively with yeast phosphatidylinositol 4-kinase isoform, Pik1. *J. Biol. Chem.* **278**, 49589–49599.
- Strahl, T., Huttner, I.G., Lusin, J.D., Osawa, M., King, D., Thorner, J., and Ames, J.B. (2007). Structural insights into activation of phosphatidylinositol 4-kinase (Pik1) by yeast frequenin (Frq1). *J. Biol. Chem.* **282**, 30949–30959.
- Taft, M.H., Behrmann, E., Munske-Weidemann, L.-C., Thiel, C., Raunser, S., and Manstein, D.J. (2013). Functional characterization of human myosin-18A and its interaction with F-actin and GOLPH3. *J. Biol. Chem.* **288**, 30029–30041.
- Tai, A.W., Bojjireddy, N., and Balla, T. (2011). A homogeneous and nonisotopic assay for phosphatidylinositol 4-kinases. *Anal. Biochem.* **417**, 97–102.
- Tan, J., and Brill, J.A. (2014). Cinderella story: PI4P goes from precursor to key signaling molecule. *Crit. Rev. Biochem. Mol. Biol.* **49**, 33–58.
- Taverna, E., Francolini, M., Jeromin, A., Hilfiker, S., Roder, J., and Rosa, P. (2002). Neuronal calcium sensor 1 and phosphatidylinositol 4-OH kinase beta interact in neuronal cells and are translocated to membranes during nucleotide-evoked exocytosis. *J. Cell Sci.* **115**, 3909–3922.
- Thomson, R., and Finkelstein, A. (2015). Human trypanolytic factor APOL1 forms pH-gated cation-selective channels in planar lipid bilayers: relevance to trypanosome lysis. *Proc. Natl. Acad. Sci. USA* **112**, 2894–2899.
- Tokuda, E., Itoh, T., Hasegawa, J., Ijuin, T., Takeuchi, Y., Irino, Y., Fukumoto, M., and Takenawa, T. (2014). Phosphatidylinositol 4-phosphate in the Golgi apparatus regulates cell-cell adhesion and invasive cell migration in human breast cancer. *Cancer Res.* **74**, 3054–3066.
- Tu, L., Chen, L., and Banfield, D.K. (2012). A conserved N-terminal arginine-motif in GOLPH3-family proteins mediates binding to coatamer. *Traffic* **13**, 1496–1507.
- Uzureau, S., Coquerelle, C., Vermeiren, C., Uzureau, P., Van Acker, A., Pilotte, L., Monteyne, D., Acolty, V., Vanhollebeke, B., Van den Eynde, B., et al. (2016). Apolipoproteins L control cell death triggered by TLR3/TRIF signaling in dendritic cells. *Eur. J. Immunol.* **46**, 1854–1866.
- Valente, A.J., Maddalena, L.A., Robb, E.L., Moradi, F., and Stuart, J.A. (2017). A simple ImageJ macro tool for analyzing mitochondrial network morphology in mammalian cell culture. *Acta Histochem.* **119**, 315–326.
- Van der Auwera, G.A., Carneiro, M.O., Hartl, C., Poplin, R., Del Angel, G., Levy-Moonshine, A., Jordan, T., Shakir, K., Roazen, D., Thibault, J., et al. (2013). From FastQ data to high confidence variant calls: the Genome Analysis Toolkit best practices pipeline. *Curr. Protoc. Bioinform.* **43**, 11.10.1–11.10.33.
- Vanhamme, L., Paturiaux-Hanocq, F., Poelvoorde, P., Nolan, D.P., Lins, L., Van Den Abbeele, J., Pays, A., Tebabi, P., Van Xong, H., Jacquet, A., et al. (2003). Apolipoprotein L-I is the trypanosome lytic factor of human serum. *Nature* **422**, 83–87.
- Vanhollebeke, B., and Pays, E. (2006). The function of apolipoproteins L. *Cell. Mol. Life Sci.* **63**, 1937–1944.
- Vanhollebeke, B., Truc, P., Poelvoorde, P., Pays, A., Joshi, P.P., Katti, R., Janin, J.G., and Pays, E. (2006). Human Trypanosoma evansi infection linked to a lack of apolipoprotein L-I. *N. Engl. J. Med.* **355**, 2752–2756.
- Vanwalleghem, G., Fontaine, F., Lecordier, L., Tebabi, P., Klewe, K., Nolan, D.P., Yamaro-Botté, Y., Botté, C., Kremer, A., Burkard, G.S., et al. (2015). Coupling of lysosomal and mitochondrial membrane permeabilization in trypanolysis by APOL1. *Nat. Commun.* **6**, 8078.
- Wan, G., Zhaorigetu, S., Liu, Z., Kaini, R., Jiang, Z., and Hu, C.A. (2008). Apolipoprotein L1, a novel Bcl-2 homology domain 3-only lipid-binding protein, induces autophagic cell death. *J. Biol. Chem.* **283**, 21540–21549.
- Wen, H., Kumar, V., Lan, X., Shoshtari, S.S.M., Eng, J.M., Zhou, X., Wang, F., Wang, H., Skorecki, K., Xing, G., et al. (2018). APOL1 risk variants cause podocytes injury through enhancing endoplasmic reticulum stress. *Biosci. Rep.* **38**, BSR20171713.
- Zhang, J.-Y., Wang, M., Tian, L., Genovese, G., Yan, P., Wilson, J.G., Thadhani, R., Mottl, A.K., Appel, G.B., Bick, A.G., et al. (2018). *UBD* modifies *APOL1*-induced kidney disease risk. *Proc. Natl. Acad. Sci. USA* **115**, 3446–3451.
- Zhao, X., Várnai, P., Tuymetova, G., Balla, A., Tóth, Z.E., Oker-Blom, C., Roder, J., Jeromin, A., and Balla, T. (2001). Interaction of neuronal calcium sensor-1 (NCS-1) with phosphatidylinositol 4-kinase beta stimulates lipid kinase activity and affects membrane trafficking in COS-7 cells. *J. Biol. Chem.* **276**, 40183–40189.

STAR★METHODS

KEY RESOURCES TABLE

REAGENT or RESOURCE	SOURCE	IDENTIFIER
Antibodies		
Rabbit anti-APOL1	Sigma-Aldrich	HPA018885; RRID:AB_1844953
Rat anti-APOL2	This study	N/A
Rat anti-APOL3	This study	N/A
Mouse anti-ARF1	Santa cruz	sc-53168; RRID:AB_2060825
Rabbit anti-Calnexin	Proteintech	10427-2AP; RRID:AB_2069033
Mouse anti-Flag	Sigma-Aldrich	F1804; RRID:AB_262044
Rabbit anti-GM130	Cell signaling	#12480; RRID:AB_2797933
Mouse anti-Golgin 97	Cell signaling	#97537; RRID:AB_2800280
Mouse anti-GOLPH3	Abcam	ab69171; RRID:AB_2279272
Rabbit anti-GOLPH3	Proteintech	19112-1AP; RRID:AB_2113342
Mouse anti-His-Tag	Sigma-Aldrich	SAB1305538; RRID:AB_2687993
Rabbit anti-INF2	Proteintech	20466-1-AP; RRID:AB_10694821
Mouse anti-MYH9	Abcam	ab55456; RRID:AB_944320
Rabbit anti-MYO18A	Proteintech	14611-1AP; RRID:AB_2201447
Rabbit anti-Myosin Light Chain (RLC)	ECM Biosciences	MP4201; RRID:AB_10837501
Rabbit anti-NCS-1	Abcam	ab129166; RRID:AB_11150438
Mouse anti-NCS-1	Santa cruz	sc-376206; RRID:AB_11008074
Mouse anti-PI(4)P	Echelon	Z-P004; RRID:AB_11127796
Mouse anti-PI(4,5)P2	Santa cruz	sc-53412; RRID:AB_630097
Rabbit anti-PI4KB	Novus Biologicals	NBP180907; RRID:AB_11040866
Rabbit anti-PI4KB	Merck-Millipore	06-578; RRID:AB_11210903
Mouse anti-TPM	Merck-Millipore	MAB2254; RRID:AB_2093368
Mouse anti-S-Tag	Sigma-Aldrich	SAB2702204
Goat anti-V5	Novus	NB600-380; RRID:AB_10003376
Mouse anti-Vinculin	Novus	NB600-1293; RRID:AB_2272814
Rabbit anti-haptoglobin	Dako	Q0330
Mouse anti-synaptopodin	Progen Biotechnik	65294
Mouse anti-podocalyxin	Millipore	MAB 430
Mouse anti-podocin	Everest Biotech	EB 12149
Mouse anti-V5 Agarose Affinity Gel antibody	Sigma-Aldrich	A7345; RRID:AB_10062721
Mouse anti-Flag M2 Affinity Gel	Sigma-Aldrich	A2220; RRID:AB_10063035
Goat anti-rabbit IgGs gold conjugates	Sigma-Aldrich	G7277; RRID:AB_259951
Mouse anti-His	Abcam	ab18184; RRID:AB_444306
peroxydase conjugated goat anti-mouse IgG	Sigma-Aldrich	DC02L; RRID:AB_437851
Mouse anti-Stag monoclonal antibody	Novagen	71549-3; RRID:AB_10806301
Bacterial and Virus Strains		
BL21(DE3)	New England Biolabs	C2527H
Biological Samples		
Natural podocytes	This study	N/A
Additional urinary podocytes	Okamoto et al., 2018	N/A
Renal biopsies	Gaillard et al., 2018	N/A
Chemicals, Peptides, and Recombinant Proteins		
Penicillin- Streptomycin	Lonza	DE17-603E
Insulin	Sigma-Aldrich	I9278

(Continued on next page)

Continued

REAGENT or RESOURCE	SOURCE	IDENTIFIER
Transferrin	Sigma-Aldrich	T8158
Selenite	Sigma-Aldrich	S5261
Fura2-AM	Eurogentec	AS-84017
Adenosine 5'-triphosphate disodium salt trihydrate	Sigma-Aldrich	10127531001
Thapsigargin	Alomone Labs	T-650
Ionomycin	Alomone Labs	I-700
Hygromycin B	InvivoGen	ant-hg-1
Doxycycline	Sigma-Aldrich	D3447
Accutase	Innovative Cell Technologies	AT104
Agar 100 Resin	Agar Scientific	AGR1031
Complete protease inhibitor	Sigma-Aldrich	11697498001
TLCK	Sigma-Aldrich	T7254
PMSF	Sigma-Aldrich	10837091001
Leupeptin	Sigma-Aldrich	11017128001
E-64	Sigma-Aldrich	10874523001
Recombinant APOL1	This study	N/A
Recombinant APOL1 null	This study	N/A
Recombinant APOL1 Δ	This study	N/A
Recombinant APOL1 Δ 1	This study	N/A
Recombinant APOL1 G1	This study	N/A
Recombinant APOL1 G2	This study	N/A
Recombinant APOL1 LZ1mut	This study	N/A
Recombinant APOL3	This study	N/A
Recombinant APOL3 null	This study	N/A
Recombinant APOL3 HCmut	This study	N/A
Recombinant PI4KB	Thermo Fisher Scientific	Ca# PV5278
Recombinant NCS-1	Abcam	Ca# ab183224
Recombinant NCS-1	This study	N/A
N-myristoylated recombinant NCS-1	This study	N/A
Recombinant NCS-1 L89K	This study	N/A
Recombinant NCS-1 F85K	This study	N/A
streptomycin	Sigma-Aldrich	S9137
IPTG	Roche	10724815001
EDTA-free protease inhibitors	Roche	11873580001
imidazole	Sigma-Aldrich	I202
tetradec-13-ynoic acid	Accela	SY034595
azido-carboxytetramethylrhodamine (TAMRA)-PEG-Biotin	Santa Cruz	SC-496240
Peptide: KYFKEKVSIGNLLLLLDNEAWNGFVAAA ELPRNEADELRKALDNLARQMIMK	GenicBio	SID1p
Peptide: LTDNEAWNGFVAAAELPRNEADELRKALD NLARQMIMK	GenicBio	LZ1p
Peptide: CGSGVKLTDVAPVSFFLVLDVVYLVYESKH LHEGAKSETAEELKKVAQELEEKLNILNNNYKIL	GenicBio	SID2p
Peptide: CGSGVKLTDVAPVGFFLVLDVVYLVYESKH LHEGAKSETAEELKKVAQELEEKLNMLNNNYKIL	GenicBio	GC1Cp
Peptide: CGSGVKLTDVAPVSFFLVLDVVYLVYESKHL HEGAKSETAEELKKVAQELEEKLNILNKKILQA	GenicBio	GC2Cp

(Continued on next page)

Continued		
REAGENT or RESOURCE	SOURCE	IDENTIFIER
Peptide: CGSGVKLTDVAPVSFFLVLDVVYLVYESKHLHE	GenicBio	HC2p
Peptide: CGSGARILSATTSGIFLALDVVNLVYESKHLHE GAKSASAEELRRQAQELEENLMELTQIQRL	GenicBio	A3Cp
Nile red dye	Sigma-Aldrich	72485
Phalloidin-iFluor 488 Reagent	Abcam	ab176753
Critical Commercial Assays		
Cell Line Nucleofector® Kit V	Lonza	VVCA-1003
Quick-DNA Plus kit	Zymo Research	D4068
NEBuilder HiFi DNA Assembly Master Mix	New England Biolabs	E2621
TruSeq Nano DNA HT Sample prep Kit	Illumina	TG-202-1003
TetOne Inducible Expression System	Clontech	634301
In-Fusion® HD Cloning System	Clontech	638920
Xfect Transfection Reagent	Clontech	631318
Western Lightning Plus	Perkin Elmer	NEL103E001EA
DNeasy Blood & Tissue Kit	QIAGEN	69504
Annexin V apoptosis detection kit	eBioscience	88-8005-72
CellMask Green Plasma Membrane Stain	ThermoFisher	C37608
CellTiter-Glo Luminescent Cell Viability Assay	Promega	G7570
MitoTracker® Red CMXRos	ThermoFisher	M7512
BCA protein assay kit	ThermoFisher	23227
Recombinant Protein G - Sepharose 4B	ThermoFisher	101243
Phosphoinositides, Strip	Echelon Biosciences	P-6001-2
Ni-NTA beads	QIAGEN	30210
Biacore Thiol Coupling Kit	GE Lifesciences	BR100557
EZ-Link NHS-PEG4-Biotin	Thermo Scientific	Ca# A39259
Direct-zol RNA kit	Zymo Research	R2051
PrimeScript RT reagent Kit with gDNA Eraser	Takara	RR047B
SYBR Premix Ex TaqII (Tli RNaseH Plus)	Takara	RR820A
ADP-Glo kinase assay kit	Promega	V6930
Deposited Data		
Proteins identified by mass spectrometry in podocyte extracts immunoprecipitated with anti-APOL1 antibody	This paper; and PRIDE archive	Data available via ProteomeXchange with identifier PXD016851
Experimental Models: Cell Lines		
WT TriFlag	This study	N/A
WT 3V5	This study	N/A
1 Δhom 3V5	This study	N/A
1KO 3V5	This study	N/A
WT APOL1 addback	This study	N/A
Δhom	This study	N/A
Δhet	This study	N/A
2KO	This study	N/A
3KO	This study	N/A
1+3KO	This study	N/A
Oligonucleotides		
CCGCCAGGCCAAAAAAGAAAAAGG	This study	T2A for
AGTGCTATCCACTGGGCCAGGATTCTCCTCG	This study	T2A rev
TGGCCAGTGGATAGCACTGAGAACGTCAT	This study	E2-Crimson for

(Continued on next page)

Continued

REAGENT or RESOURCE	SOURCE	IDENTIFIER
GCTGATCAGCGAGCTCTAGTTAGCCCTGGAACAGGT GGTGGCGGG	This study	E2-Crimson rev
CACCGCACTGGTCTGGGGTCAGT	This study	APOL3 sgRNA for
AAACACTGACCCAGACCAGTGC	This study	APOL3 sgRNA rev
TTGCATGCCTGCAGGTGCGACTATGAGGCAGATG CTCTCTACG	This study	APOL3 ORF for
ACTTCCCAGCGGGCCCTGGAACAATACTTCCAG ATCACTGCCGTGGGTATGGCATGGATTCAGA	This study	APOL3 ORF rev
CTGTACAAGTAGCCCCAGACCAGTGCAGCC	This study	APOL3 UTR for
AATTCGAGCTCGGTACCCGGTTACACACAGGG CACTCAGC	This study	APOL3 UTR rev
CCAGGGCCCCTGGAAGTGGCAAACCGATTCCG AACCCGCTTCTTGGTCTAGACAGCACCCGGTGGCAG TGGAGAGGGCAGA	This study	V5-GFP for
GTCTGGGGCTACTTGTACAGCTCGTCCATGCC	This study	V5-GFP rev
CCAGGGCCCCTGGAAGTATTATAAGGATCATG ATGGTGACTACAAAGACCATGATATCGATTACAAAG ATGATGACAAGGGTGGCAGTGGAGAGGGCAGA	This study	TriFlag-GFP for
GTCTGGGGCTACTTGTACAGCTCGTCCATGCC	This study	TriFlag-GFP rev
CCCTCGTAAAGAATTCATGTCAGAGGAAGCTGGA GCGAGG	This study	APOL1 TetOne for
GCAGAGATCTGGATCCTCACAGTCTTGGTCCGC CTGCAG	This study	APOL1 TetOne rev
GTCAGTGAAGCAATCTCAGC	This study	APOL1 exon 7 Fw
CATATCTCTCCTGGTGGCTG	This study	APOL1 exon 7 Rv
CCAGCTTTGCAATCATGAGATTC	N/A	APOL1 Ex2-Forward
TTCCTCTGCCCTCACTCC	N/A	APOL1 Ex4 Reverse
ATGGAGGGAGCTGCTTTG	N/A	APOL1 Ex3-Forward
TGCATCTGGGTGCAACAAA	N/A	APOL1 Ex 3-5 Forward
GATACTGCTCTCTGGGTCCAT	N/A	APOL1 Ex5-Reverse
Recombinant DNA		
U6gRNA-Cas9-2A-GFP (TGTGCTGCTGGTCTTTA TCGTGG sgRNA)	Sigma-Aldrich	CRISPR APOL2
U6gRNA-Cas9-2A-GFP (TAGAACATATGCAGCTA TTGAGG sgRNA)	Sigma-Aldrich	CRISPR APOL3 exon 5
U6gRNA-Cas9-2A-GFP (AACCAGCATTGACCGA TTGAAGG sgRNA)	Sigma-Aldrich	CRISPR APOL3 exon 5
U6gRNA-Cas9-2A-GFP (AAGTAAGCCCCTCGGT GACTGGG sgRNA)	Sigma-Aldrich	CRISPR APOL1 exon 3
U6gRNA-Cas9-2A-GFP (AGTGCTTTGATTCGTAC ACGAGG sgRNA)	Sigma-Aldrich	CRISPR APOL1 exon 5
pGEM-T Easy vector	Promega	A137A
pSpCas9(BB)-2A-E2Crimson	This study	N/A
pSpCas9(BB)-2A-GFP	Ran et al., 2013	Addgene plasmid # 48138
pApoL3-HRV-V5-2A-GFP	This study	N/A
pApoL3-HRV-TriFlag-2A-GFP	This study	N/A
pCDF-Duet1	Novagen	N/A
Software and Algorithms		
Trimmomatic v035	Bolger et al., 2014	http://www.usadellab.org/cms/?page=trimmomatic
BWA mem v0.7.15	Li, 2013	https://github.com/lh3/bwa

(Continued on next page)

Continued		
REAGENT or RESOURCE	SOURCE	IDENTIFIER
GATK v3.6-0	Van der Auwera et al., 2013	https://github.com/broadinstitute/gatk/
Snpeff 4.2	Cingolani et al., 2012	http://snpeff.sourceforge.net/
Picard v2.6.0	Broad Institute	https://github.com/broadinstitute/picard
Samtools 1.3.1		https://github.com/samtools/samtools
ImageJ		https://imagej.nih.gov/ij/
MTrackJ ImageJ plugins	Meijering et al., 2012	https://imagescience.org/meijering/software/mtrackj/
MicroP	Peng et al., 2011	http://bmi.ym.edu.tw/jypeng/
MiNA	Valente et al., 2017	https://github.com/StuartLab/MiNA
iTEM software	Olympus GMBH	N/A
JACoP plugins		https://imagej.nih.gov/ij/plugins/track/jacop.html
BIAevaluation 4.1.1.1.	GE Lifesciences	N/A
Octet Data Acquisition V10.0	ForteBio/ Molecular Devices	N/A
Octet Data Analysis V10.0	ForteBio/ Molecular Devices	N/A
MaxChelator Ca-EGTA Calculator v1.3	Schoenmakers et al., 1992	https://somapp.ucdmc.ucdavis.edu/pharmacology/bers/maxchelator/index.html
Graph-pad Prism 8	Graphpad prism	https://www.graphpad.com/scientific-software/prism/
Softmax Pro 5.4.4	Molecular devices	Molecular devices
Other		
DMEM-HAM's F-12	Lonza	BE04-687F/U1
Eight wells Falcon culture chamber	Falcon	54118
Human fibronectin-coated 96-well Microplate	R&D Systems	CWP001
IbidiTreat 8 well microslides	Ibidi	80826
Formvar-carbon-coated copper grids	Agar Scientific	AGS162-3
SDS-polyacrylamide pre-cast gels	Biorad	456-1033
glass beads Lysing Matrix B	MP Biomedicals	SKU 116911050
Biacore CM5	GE Lifesciences	29149604
Biosensor / Streptavidin (SA) Pack	ForteBio/ Molecular Devices	Ca#18-5020
Biacore Thiol Coupling Kit	GE Lifesciences	BR100557
EZ-Link NHS-PEG4-Biotin	Thermo Scientific	Ca# A39259

LEAD CONTACT AND MATERIALS AVAILABILITY

Further information and requests for reagents may be directed to, and will be fulfilled by the corresponding author Etienne Pays (epays@ulb.ac.be). All unique/stable reagents generated in this study are available from the Lead Contact with a completed Materials Transfer Agreement.

EXPERIMENTAL MODEL AND SUBJECT DETAILS

Immortalized podocytes

The conditionally immortalized human podocyte cell line described in [Saleem et al. \(2002\)](#) was obtained from Dr. M.A. Saleem (University of Bristol, UK).

Urinary G0 and G2 podocytes

Human G0 and G2 podocytes exfoliated into urine were immortalized, sub-cloned and cultivated as described below (Figure S12). This study was approved by Ethical Research Committee of the University Hospital/KU Leuven (S61246). The participants were recruited from the African community living in Belgium after signing of the informed consent form. Samples were de-identified. Neither sex nor age is known.

Additional urinary podocytes

Control G0/G0, FSGS G1/G2 and HIVAN G1/G2 urinary podocytes described in Okamoto et al. (2018) were obtained from Dr. J. Kopp (NIH, USA).

Renal biopsies

G0/G0, G1/G1 and G2/G2 human kidney biopsy tissues were obtained from a cohort of living kidney donors of African origin, described in Gaillard et al. (2018). All biopsies were performed as rejection screening three months post-transplantation as part of routine work-up. All patients gave informed and signed consent. Samples were de-identified. Neither sex nor age is known.

METHOD DETAILS

Cultivation of immortalized podocytes

Cultivation of these cells was performed essentially as described (Saleem et al., 2002). Briefly, cells were grown to confluence at 33°C, at which point they were trypsinized and reseeded in fresh flasks at a dilution of between 1:3 and 1:5. Before switching to 37°C, cells were grown to 70 to 80% confluence. At both temperatures, cells were fed with fresh medium 3 times per week. Podocytes were used after 7 to 14 days of differentiation.

Generation of APOL-edited podocytes

CRISPR-Cas9 and green fluorescent protein (GFP) fusion protein expression vectors U6gRNA-Cas9-2A-GFP guide were purchased from Sigma-Aldrich. These vectors allow the co-expression of GFP and Cas9 from the same mRNA via a 2A peptide linkage, which enables tracking of transfection efficiency. The RNA guide sequences are listed in Table S1A. Plasmids were transfected into immortalized podocytes using Cell Line Nucleofector® Kit V (Lonza, Bale, Switzerland) and program T-020 (2 µg plasmid per 2 × 10⁶ podocytes) with Nucleofector II apparatus (Lonza) following manufacturer's instructions. The GFP positive cells were sorted using a FACSAria III cell sorter (BD Biosciences, Franklin Lakes, USA) and seeded at one cell per 3 wells in 96 well-plates. The clones were screened by western blot analysis for the lack of targeted APOL expression. The genomic DNA of the selected clones was extracted using the Quick-DNA Plus kit (Zymo Research, Irvine, USA) following manufacturer's instructions. The genomic region targeted by the CRISPR/Cas9 procedure was amplified by PCR and cloned into pGEMTeasy vector (Promega). Ten clones were sequenced and the genome of podocyte cell lines chosen to pursue the study was fully sequenced. The sequencing results are summarized in Tables S1B–S1E.

In situ C-terminal tagged versions of APOL3

All the anti-APOL3 antibodies that were tested, either raised in our laboratory or commercially available, exhibited non-specific reaction (see Figure 1B). Therefore, we generated podocyte cell lines which express the V5, TriFlag or GFP tags in fusion with APOL3. The CRISPR-Cas9 and E2 Crimson fluorescent protein expression vector pSpCas9(BB)-2A-E2Crimson was generated as follow. The T2A fragment was PCR-amplified from pSpCas9(BB)-2A-GFP vector using the 5'- CCGGCCAGGCAAAAAGAAAAGG –3' and 5'- AGTGCTACTCCACTGGGCCAGGATTCTCCTCG –3' primers. The E2-Crimson fragment was PCR-amplified using the 5'- TGGCCAG TGGATAGCACTGAGAACGTCAT –3' and 5'- GCTGATCAGCGAGCTCTAGTTAGCCCTGGAACAGGTGGTGGCGGG –3' primers. The T2A and E2-Crimson fragments were cloned into EcoRI digested pSpCas9(BB)-2A-GFP vector (Ran et al., 2013) using NEBuilder HiFi DNA Assembly Master Mix (New England Biolabs, Ipswich, USA) following manufacturer's instructions to generate pSpCas9(BB)-2A-E2Crimson. The CRISPR-Cas9 guide RNA sequence targeting APOL3 was generated by cloning the annealed 5'- CACCGCACT GGTCTGGGGTCAGT –3' and 5'- AAACACTGACCCAGACCAGTGC –3' primers into the BbsI restricted pSpCas9(BB)-2A-E2Crimson vector.

The C-terminal APOL3 tagging constructs pApoL3-HRV-V5-2A-GFP and pApoL3-HRV-TriFlag-2A-GFP were generated as follow. The APOL3 ORF and APOL3 UTR fragments were PCR-amplified from podocyte gDNA using respectively the 5'- TTGCATGCCTGC AGGTCGACTATGAGGCAGATGCTCTCTACG –3' and 5'- ACTTCCCAGCGGGCCCTGGAACAATACTTCCAGATCACTGCCGTGG GTATGGCATGGATTGAGA –3' primers, and the 5'- CTGTACAAGTAGCCCCAGACCAGTGCAGCC –3' and 5'- AATTCGAGCTCGG TACCCGGTTACACACAGGGCACTCAGC –3' primers. The V5-GFP and TriFlag-GFP fragments were PCR-amplified from the pSpCas9(BB)-2A-GFP vector S1 using respectively the 5'- CCAGGGCCCCGCTGGGAAGTGGCAAACCGATTCCGAACCCGCTT CTTGGTCTAGACAGCACCGGTGGCAGTGGAGAGGGCAGA –3' and 5'- GTCTGGGGCTACTTGTACAGCTCGTCCATGCC –3' primers, and the 5'- CCAGGGCCCCGCTGGGAAGTATTATAAGGATCATGATGGTACTACAAAGACCATGATATCGATTACAAAGAT GATGACAAGGGTGGCAGTGGAGAGGGCAGA –3' and 5'- GTCTGGGGCTACTTGTACAGCTCGTCCATGCC –3' primers. The APOL3 ORF, APOL3 UTR and either V5-GFP or TriFlag-GFP fragments were cloned into XbaI / BamHI restricted pUC18 vector using

NEBuilder HiFi DNA Assembly Master Mix (New England Biolabs) following manufacturer's instructions to generate the pAPOL3-HRV-V5-2A-GFP or pAPOL3-HRV-TriFlag-2A-GFP tagging constructs respectively. The tagging constructs were linearized using Sall and KpnI restriction enzymes before use.

Podocytes were transfected using APOL3-targeted pSpCas9(BB)-2A-E2Crimson vector and pAPOL3-HRV-V5-2A-GFP vectors to generate the WT TriFlag, WT 3V5, 1 Δ hom 3V5 and 1KO 3V5 cell lines. Both induction of cell death and APOL3 expression by poly(I:C) remained unaltered in the podocyte cell lines expressing V5-tagged APOL3 (see [Figures 1B and 1C](#)).

Genomic Analysis of the edited podocytes

Genome libraries were prepared with the Illumina TruSeq Nano DNA HT Sample prep Kit and sequenced on a HiSeq X-Ten platform with paired-end reads of 150 bp (BGI, Hong Kong). Low quality regions of the reads were trimmed using Trimmomatic v0.35 ([Bolger et al., 2014](#)). The reads were aligned to the hg38 reference human genome with the Burrows-Wheeler Aligner (BWA) mem tool v0.7.15 ([Bolger et al., 2014](#); [Li, 2013](#)), using default parameters. The resulting sam file was converted to bam, sorted, merged per sample and indexed with samtools 1.3.1 ([Li, 2011](#)). Duplicate reads were marked with the Picard v2.6.0 Mark Duplicates tool and variant calling was performed with the Genome Analysis Toolkit v3.6-0 Haplotype Caller (GATK) ([Van der Auwera et al., 2013](#)). Variants were consequently filtered with the Variant Quality Score Recalibration following exactly the parameters and training sets recommended by GATK. Finally, variants were annotated with SnpEFF 4.2 ([Cingolani et al., 2012](#)). SNPs and INDELS were compared between the WT podocyte cell line and the CRISPR/Cas9 mutant cell lines in genome regions with minimal coverage of 10-fold for homozygous variants and minimal coverage of 20-fold for heterozygous variants.

The genomes of all cell lines were sequenced with at least 26.64-fold average coverage, 97.91% of the genome covered at least 10-fold and 81.58% 20-fold ([Table S1B](#)). In total, 3,206,618 SNPs and 864,694 INDELS passed the GATK Variant Quality Score Recalibration filter after aligning to the Hg38 reference genome. In a first phase, the genomes of the podocyte cell lines were manually checked for the CRISPR/Cas9-directed edits in the APOL1 and APOL3 genes ([Table S1C](#)). The APOL1KO 1G3, APOL1 Δ 3G3 and APOL3KO C3 genomes showed homozygous INDELS in the targeted regions of APOL1 or APOL3, and all caused a 100% frameshift. The APOL1 Δ 3D8 genome had 3 heterozygous INDELS in APOL1, which complemented each other to cause a 100% frameshift. We additionally checked all the genomes for off-target CRISPR/Cas9 edits to be sure that the observed phenotypes are exclusively caused by the targeted modifications in APOL1 and APOL3. The off-target SNPs and INDELS are summarized in [Tables S1D and S1E](#). Only 1 homozygous SNP of moderate impact was detected in the HEG1 (Arg101Ser) gene of the APOL3KO C3 cell line. The other podocyte cell lines did not contain any homozygous SNPs/INDELS of moderate or high impact. All cell lines did contain heterozygous SNPs/INDELS of moderate and high impact. The only two genes showing heterozygous SNPs/INDELS possibly related with the phenotype, thus, only shared between APOL1 Δ and APOL3KO, were MED1 (Mediator of RNA polymerase II transcription subunit 1) and POT1 (Protection of telomeres protein 1), two genes for general chromatin organization that are not specifically related to actomyosin control.

APOL1 inducible cell line

The WT APOL1 addback cell line was generated using TetOne Inducible Expression System (Clontech, Mountain View, USA) following manufacturer's instructions. Briefly, APOL1 was PCR-amplified using primers 5'-CCCTCGTAAAGAATTCATGTCAGAGGAAGCTGGAGCGAGG-3' and 5'-GCAGAGATCTGGATCCTCACAGTTCTTGGTCCGCCTGCAG-3' and cloned into pTetOne vector using In-Fusion[®] HD Cloning System (Clontech). The pTetOne vector was transfected into podocytes using Xfect transfection reagent (Clontech). Hygromycin resistant cells were screened for APOL1 induction following doxycycline induction.

Generation of G0 and G2 podocyte lines ([Figure S12](#))

Sera analysis

Sera were collected from 19 individuals, and tested for their trypanolytic activity on different *Trypanosoma brucei* subspecies, as well as for their APOL1 content ([Figure S12A](#)). Sera lytic for *T. b. rhodesiense* were also analyzed for the presence of haptoglobin with anti-human haptoglobin (Dako), ([Figure S12B](#)). The primary antibody was detected by anti-rabbit HRP conjugate and ECL substrates (Perkin Elmer, Waltham, USA). The selected APOL1 G2/G2 genotype carrier sample was number 12. This patient suffered chronic kidney disease stage 4 post perinatal asphyxia.

APOL1 Genotyping

DNA was extracted from whole blood samples using QIAGEN kits following the manufacturer's instructions. APOL1 genotyping was performed for the renal risk allele G2 (6 base-pair deletion, rs71785313). The exon 7 (883 bp) of APOL1 was amplified using gene-specific primer pairs (Fw5'-GTCAGTCTGAGCCAAATCTCAGC-3' / Rv5'-CATATCTCTCCTGGTGGCTG-3'). Subsequently, DNA sequencing was performed with an ABI 3100XL High-Throughput DNA Sequencer (Applied Biosystems, Foster City, USA).

Cultivation of podocytes exfoliated into urine

Freshly voided urine was collected from the patient carrying APOL1 high risk genotype (G2/G2) and cells exfoliated into urine were cultured as previously described ([Ivanova et al., 2016](#)). In brief, urine was centrifuged at 300 g for 5 min, the pellet was washed in PBS and re-suspended in podocyte growth medium composed of DMEM-HAM's F-12 (Lonza) with 10% fetal bovine serum (GIBCO), 50 IU/ml penicillin, 50 mg/ml streptomycin (Lonza), 5 μ g/ml insulin, 5 μ g/ml transferrin and 5 ng/ml selenium (Sigma). Cells were immortalized and sub-cloned using a temperature-sensitive SV40-TERT viral system ([Saleem et al., 2002](#)). Briefly, cultures of primary

human podocytes were infected with retrovirus-containing supernatants from the packaging cell line (PA317). Cells in log-phase growth were exposed to filtered (0.45 μm) supernatant mixed 1:1 with growth medium plus 8 $\mu\text{g/ml}$ polybrene. After 24 h, cultures were refed with fresh growth medium and grown for an additional 7 days to confluence. The culture medium was then supplemented with 0.5 mg/ml G418 (Life Technologies BRL, Life Technologies, Paisley, UK) until selection was complete (7 to 10 days). Infection, selection, and continuous culture were carried out at 33°C. Clonal cells were grown at permissive temperature of 33°C and, prior to the experiments, incubated at 37°C for 7 days to ensure growth arrest and complete differentiation. *APOL1* WT podocytes, used as controls, were generated from a Caucasian patient using the same methodology.

***APOL1* sequence of the G2/G2 podocyte cells**

The gDNA was isolated from G2/G2 clones and the targeted exon 7 (883 bp) of *APOL1* was amplified and sequenced as described above (Figure S12C).

Immunofluorescence

Immunofluorescence analysis was performed for the podocyte specific proteins synaptopodin, podocalyxin and podocin, as previously described (Ivanova et al., 2016) (Figure S12D). Briefly, cells grown on glass coverslips were fixed with 4% paraformaldehyde for 10 min at room temperature and washed once in PBS. Cells were permeabilized in 0.1% Triton X-100 for 5 min and washed twice with PBS. Blocking solution (0.5% bovine serum albumin, 0.2% gelatin, 0.5% fetal bovine serum in PBS) was added to cells for 20 min followed by 1 h of incubation with appropriate concentrations of primary antibodies in blocking solution. Cells were washed with PBS and incubated with secondary antibodies (1:1000) diluted in blocking solution. Coverslips were washed in PBS and mounted on glass slides. Images were acquired using a Zeiss Axio Observer Z1 with a 20x objective.

Analysis of renal biopsies

For each glomerulus the mean level of fluorescence was normalized with respect to the mean level of the control surface. In the case of WT samples (G0 individuals), two biopsies were analyzed (AP13.1921 and AP13.6775). For the G1 samples the four biopsies were AP08.4028, AP12.8491, AP15.5049 and AP15.7024, whereas for G2 the biopsy analyzed was AP11.4066.

Apoptosis assays

AnnexinV staining was performed using Annexin V apoptosis detection kit (eBioscience, San Diego, USA) according to manufacturer's instructions. The samples were analyzed by flow cytometry within 30 min.

Cell morphology analysis

Podocytes were grown in 8 wells Falcon culture chamber (Corning, USA) and stained with CellMask Green Plasma Membrane Stain (ThermoFisher) according to manufacturer's protocol. Images were acquired using a Zeiss Axio Observer Z1 with a 20x objective. Cell area and perimeter were quantified with ImageJ.

Cell adhesion assays

Cells were collected using Accutase (Innovative Cell Technologies, San Diego, USA), resuspended at similar density, loaded into human fibronectin-coated 96-well Microplate (R&D Systems, Minneapolis, USA) and incubated for 1 h at 37°C with 5% CO₂. The cells were subsequently washed 5 times with phosphate-buffered saline (PBS) and numbered using CellTiter-Glo Luminescent Cell Viability Assay (Promega, Madison, USA) following manufacturer's instructions.

Single cell motility assays

Podocytes were plated in IbiTreat 8 well microslides (Ibidi, Martinsried, Germany) at 10³ cells per well dilution and incubated for 10 h at 37°C and 5% CO₂ using Zeiss Axio Observer Z1. Imaging was performed using the 10x objective and the automatic heated stage for live cell imaging. Images were taken from each position of the array every 5 min for 8 h. The individual images from each position were combined into stacks using ImageJ software. Cell tracking was performed using the MTrackJ plugin (Meijering et al., 2012). Individual trajectories of 30 randomly selected cells from each group were plotted using Excel software.

Mitochondria analysis

Podocytes were grown in 8 wells Falcon culture chamber (Corning) and stained with MitoTracker® Red CMXRos (ThermoFisher) for 30 min at 37°C, washed with PBS and fixed for 30 min in 4% paraformaldehyde. Images were acquired using a Zeiss LSM710 confocal scanning microscope with a 40x 1.4NA oil immersion objective. Mitochondria morphology was analyzed using MicroP and MiNA softwares (Peng et al., 2011; Valente et al., 2017).

Transmission Electron Microscopy

TEM analysis was performed as described (Fontaine et al., 2017). Briefly, cells were fixed for 1 h at room temperature in 2.5% glutaraldehyde in culture medium, and postfixed in 2% OsO₄ in the same buffer. After serial dehydration in increasing ethanol concentrations, samples were embedded in agar 100 (Agar Scientific Ltd., United Kingdom) and left to polymerize for 2 days at 60°C. Ultrathin sections (50 to 70 nm thick) were collected in Formvar-carbon-coated copper grids by using a Leica EM UC6 ultramicrotome and

stained with uranyl acetate and lead citrate. Observations were made on a Tecnai10 electron microscope (FEI), and images were captured with an Olympus VELETA camera and processed with iTEM software (Olympus GMBH, Germany).

Golgi size measurements

On TEM images the Golgi compartment was identified by its unique morphological characteristics. Regions of interest around the Golgi stacks and the TG network were encircled by the pen tool of the iTEM software (Olympus GMBH) and the integrated perimeter and surface were automatically calculated.

Western Blot analysis

Cells were lysed in RIPA buffer (1% NP-40 or 1% CHAPS, 0.1% SDS, 0.5% deoxycholate sodium salt in PBS) supplemented with complete protease inhibitor (Roche, Bale, Switzerland). The protein concentration was determined using BCA protein assay kit (ThermoFisher). Equivalent amounts of protein were separated on SDS–polyacrylamide pre-cast gels (Biorad, Hercules, USA) and processed for western blotting.

Immunoprecipitation

Protein lysates in RIPA buffer with 1% NP-40 or 1% CHAPS (300 μ g to 1 mg) were incubated with primary antibody overnight at 4°C, followed by incubation with 20 μ L of pre-blocked protein G-Sepharose beads for 1 h. Following four washes in RIPA buffer and one wash in PBS, the immune complexes were eluted in non-reducing Laemmli buffer and analyzed by western blotting. Immunoprecipitation of V5- and Flag-tagged protein complexes were performed using anti-V5 Agarose Affinity Gel antibody and anti-Flag M2 Affinity Gel respectively, according to the manufacturer (Sigma).

Immunofluorescence

Cells were grown in Falcon culture chambers (8 wells plate). PBS-washed cells were fixed in 4% paraformaldehyde for 10 min at room temperature, treated with 0.1% (v/v) Triton X-100 in Tris-buffered saline for 10 min and incubated for 1 h in Tris-buffered saline with 5% bovine serum albumin. Nuclei were stained with DAPI. PI(4)P and PI(4,5)P2 immunostainings were performed as previously described (Elong Edimo et al., 2016). Briefly, cells were fixed in formaldehyde 4% and 0.2% glutaraldehyde for 15 min on ice for PI(4,5)P2 staining or 15 min in 2% PFA at room temperature for PI(4)P staining. After three washes with PBS containing 50 mM NH₄Cl, cells were permeabilized either in buffer A (137 mM NaCl, 2.7 mM KCl, 20 mM PIPES (pH 6.8)) containing 0.1% saponin, 5% normal goat serum (NGS), 5% normal human serum (NHS) for 45 min on ice for PI(4,5)P2 staining or 5 min in buffer A containing 20 μ M digitonin and 45 min in PBS NH₄Cl, 5% NGS for PI(4)P staining. Anti-PI(4,5)P2 or anti-PI(4)P antibodies were incubated 16 h at 4°C. After 3 washes of 5 min in PBS NH₄Cl, cells were incubated with anti-mouse IgM -Alexa 488 for 1 h at room temperature. Primary and secondary antibodies were diluted in Buffer A containing 0.1% NGS and 5% NHS for PI(4,5)P2 staining or buffer A containing 5% NHS for PI(4)P staining. Post-fixation was performed (PFA 2% 10 min on ice and 5 min RT for PI(4,5)P2 staining, 5 min in 4% PFA at RT for PI(4)P staining) and after final washes in PBS NH₄Cl cells were mounted. Images were acquired sequentially at each laser excitation wavelength using a LSM710 confocal scanning microscope with a 63x1.4NA oil immersion objective (Zeiss). Co-localization analysis was performed using JACoP (Just Another Colocalization Plugin) for ImageJ (Bolte and Cordelières, 2006). The co-localization was quantified using Manders coefficients calculated after Costes automated threshold. Detailed analysis concluded to the validity of this method (Dunn et al., 2011). The extent of focal adhesion foci and Golgi size (expressed as the % of nuclear periphery) (Dippold et al., 2009) were measured using ImageJ.

Immunogold labeling

For immunogold detection by ultrathin cryosectioning (Tokuyasu), cells were fixed in 4% paraformaldehyde–0.5% glutaraldehyde–0.1 M cacodylate buffer (pH 7.2) for 15 min at room temperature, embedded in 10% gelatin and 2.3 M sucrose, and frozen in liquid nitrogen. Sectioning of frozen samples was done on a Leica EM UC7 ultramicrotome at 70 nm. Sections on carbon-Formvar grids were probed with a rabbit anti-APOL1 antibody and a mix of anti-rabbit IgGs gold conjugates (5 nm and 10 nm) and then mounted in methylcellulose–1% uranyl acetate films. Observations were made on a Tecnai 10 electron microscope (FEI) at 100 kV and images were captured with an Olympus VELETA camera and processed with iTEM software (Olympus GMBH, Germany).

Cellular fractionation

Fractionation of podocyte extracts was performed as described (Sibley et al., 1995). Briefly, cells were washed in Hanks' balanced salt solution supplemented with 1 mM EGTA and 10 mM HEPES and resuspended at 10⁸ cells/ml in calcium/magnesium-free PBS containing 1 mM EGTA, and then subjected to three freeze-thaw cycles or to sonication for three, 15 s pulses at an intensity of 5 using a micro-tip probe (Branson Sonifier 185). Protease inhibitors were included in all steps of cell fractionation at the following concentrations: 10 μ g/ml TLCK, 10 μ g/ml a-PMSF, 1 μ g/ml leupeptin and 10 μ g/ml E-64. Lysates were centrifuged at 2,500 g to remove cell nuclei and debris. The supernatant was further centrifuged at 100,000 g for 2 h in a TL-100.3 rotor using a Beckman Optima TL table-top ultra-centrifuge. The membrane pellet was washed once with 1 mM EGTA, 100 mM sucrose, 50 mM Tris-HCl (pH 7.6).

Mass spectrometry

Peptides were analyzed by using nano-LC-ESI-MS/MS maXis Impact UHR-TOF (Bruker, Bremen, Germany) coupled with a UPLC Dionex UltiMate 3000 (Thermo). Lanes were excised from SDS-PAGE gels and proteins were digested with trypsin by in-gel digestion. The gel pieces were washed twice with distilled water and then shrunk with 100% acetonitrile. The proteolytic digestion was performed by the addition of 6 μ l of modified trypsin (Promega) suspended in 50 mM NH_4HCO_3 cold buffer. Proteolysis was performed overnight at 37°C. The supernatant was collected and the eluates were kept at -20°C prior to analysis. The digests were separated by reverse-phase liquid chromatography using a 75 μm x 250 mm reverse phase Thermo column (Acclaim PepMap 100 C18) in an Ultimate 3000 liquid chromatography system. Mobile phase A was 95% of 0.1% formic acid in water and 5% acetonitrile. Mobile phase B was 0.1% formic acid in acetonitrile. The digest (15 μ l) was injected, and the organic content of the mobile phase was increased linearly from 4% B to 35% in 35 min and from 35% B to 90% B in 5 min. The column effluent was connected to a Captive Spray (Bruker). In survey scan, MS spectra were acquired for 0.5 s in the m/z range between 50 and 2200. The 10 most intense peptide ions 2+ or 3+ were sequenced. The collision-induced dissociation (CID) energy was automatically set according to mass to charge (m/z) ratio and charge state of the precursor ion. MaXis and Thermo systems were piloted by Compass HyStar 3.2 (Bruker). Peak lists were created using DataAnalysis 4.1 (Bruker) and saved as MGF file for use with ProteinScape 3.1 (Bruker) with Mascot 2.4 as search engine (Matrix Science). Enzyme specificity was set to trypsin, and the maximum number of missed cleavages per peptide was set at one. Carbamidomethylation was allowed as fixed modification, oxidation of methionine and Gln- > pyro-Glu were allowed as variable modifications. Mass tolerance for monoisotopic peptide window was 7 ppm and MS/MS tolerance window was set to 0.05 Da. The peak lists were searched against the mammalian taxonomy from UNIREF 100. The list of proteins identified in 1% NP-40 extracts by mass spectrometry proteomics data have been deposited to the ProteomeXchange Consortium via the PRIDE partner repository with the dataset identifier PXD016851 and 10.6019/PXD016851.

In vitro lipid binding assays

Lipid binding assays were performed on lipid-coated strips as described (Wan et al., 2008). Briefly, nitrocellulose membranes pre-spotted with various indicated lipid species (P-6001, P-6002, Echelon, Salt Lake City, UT) were blocked in 3% fat-free BSA for 60 min at room temperature, probed with recombinant APOLs (~ 100 ng/ml) in 3% fat-free BSA in TBST for 1 h at room temperature, followed by primary anti-APOL antibody, secondary goat anti-rabbit antibody conjugated with horseradish peroxidase, and ECL detection and imaging.

Liposome association assays

Assays were performed by incubating 5 μ l of 5 mM liposomes with 2 μ g of recombinant protein in a final volume of 50 μ L in 0.1 mM CaCl_2 , 0.1 mM MgCl_2 , 30 mM NaCl, 1 mM DTT, 50 mM Tris HCl (pH 7.5). Liposomes were pelleted by centrifugation at 16,000 g for 10 min. Lipid pellets were washed, and supernatant and pellet fractions were analyzed by gel electrophoresis on a 10% polyacrylamide gel and processed for western blotting with anti-APOL1 and APOL3 antibodies.

Y2H interaction assays

The Y2H cDNA library construction and screening, and all protein Y2H interaction analyses were performed by Hybrigenics SA (Paris, France). For interaction analysis, the bait sequence was PCR-amplified and cloned in frame with the LexA DNA binding domain (DBD) into pB27 as N-terminal fusion (LexA-APOL1Nter). The prey fragments were extracted from the screening of APOL sequences with the human podocyte library. They were cloned in frame with the Gal4 activation domain as N-terminal fusion into plasmid pP6. The AD construct was checked by sequencing. Bait and prey constructs were transformed in the yeast haploid cells L40 Δ Gal4 (MAT α) and YHGX13 (Y187 ade2-101::loxP-kanMX-loxP, MAT α), respectively. The diploid yeast cells were obtained using a mating protocol with both yeast strains. These assays are based on the HIS3 reporter gene (growth assay without histidine). As negative controls, the bait plasmid was tested in the presence of empty prey vector (pP7) and the prey plasmid was tested with the empty bait vector (pB27). The interaction between SMAD and SMURF was used as positive control. Interaction pairs were tested in duplicate as two independent clones were picked for the growth assay. For each interaction, several dilutions of the diploid yeast cells (culture normalized at 5×10^7 cells) and expressing both bait and prey constructs were spotted on several selective media. The DO-2 selective medium lacking tryptophan and leucine was used as a growth control and to verify the presence of both the bait and prey plasmids. The different dilutions were also spotted on a selective medium without tryptophan, leucine and histidine (DO-3). Different concentrations of 3-amino-1,2,4-triazole (3-AT), an inhibitor of the HIS3 gene product, were added to the DO-3 plates to increase stringency of the interaction.

pDUET assays

Gene co-expression assays in *E. coli* were performed as described (Lecordier et al., 2009). Cellular lysates usually contained 1% CHAPS, but in some cases 1% NP-40 was used instead, as indicated. Briefly, cultures of BL21(DE3) strains transfected with pCDF-Duet1 constructs were grown at 37°C in LB containing 50 μ g/ml streptomycin and 1% glucose from freshly plated colonies until OD600 reached 0.7 to 0.8. Cultures were centrifuged and bacteria pellet was resuspended in fresh medium without glucose and distributed in 3 flasks to perform induction and copurification in triplicate. Expression of recombinant proteins was induced by addition of 1 mM IPTG overnight at 20°C and 80 rpm. Cell density was measured by OD600 and bacteria were centrifuged and resuspended in (10% of culture volume \times OD600) in cold hypotonic buffer (50 mM MES pH 6.0 or pH 7.0) containing EDTA-free pro-

tease inhibitors (Roche). Bacteria were lysed by Fast Prep 24 (MP Biomedicals) with 1/10 volume of glass beads (Lysing Matrix B, MP Biomedicals), for 3 × 30 s at 6 m/s. Cell lysate was complemented by 0.6 M NaCl, 1% Triton X-100, 20 mM imidazole, and vortexed vigorously. Cell debris were pelleted by centrifugation for 15 min at 16,000 g, and the supernatant was applied onto Ni-NTA beads (QIAGEN) equilibrated in the same buffer, for 2 h at 4°C. After binding the beads were washed with 20 volumes of beads with cold binding buffer and the bound proteins were eluted with 2 volumes of SDS-PAGE sample buffer. Supernatant (total soluble fractions) and bound fractions were analyzed by western blotting. His tag was revealed with anti-His mouse monoclonal antibody and peroxidase conjugated anti-mouse antibody. Stag was detected by anti-Stag monoclonal antibody (Novagen) and peroxidase conjugated anti-mouse antibody. Peroxidase activity was revealed by ECL (Western Lighting Chemiluminescence Reagent PLUS, Perkin Elmer).

N-myristoylated recombinant NCS-1

In order to produce N-myristoylated NCS-1 in *E. coli*, the gene encoding human N-myristoyltransferase (hsNMT1) was inserted next to the NCS-1 gene in the pDUET vector, and both proteins were expressed in the presence of myristic acid (Glück et al., 2010; Price et al., 2012). To check N-myristoylation, the myristate analog 13-tetradecynoic acid (alkynyl myristic acid) was used. *E. coli* extracts were incubated with the capture reagent azido-carboxytetramethylrhodamine (TAMRA)-PEG-Biotin (Az-TB), and the TAMRA fluorophore was detected in gels from SDS-PAGE as described in Glück et al. (2010) and Price et al. (2012). Briefly, the hsNMT1 substrate myristic acid was added 10 min before induction to a final concentration of 50 μM. Myristic acid was supplied as a freshly prepared 5 mM stock solution containing 0.6 mM BSA (Sigma). The pH of the stock solution was adjusted with NaOH to 9 and briefly heated to 50°C for complete solubilization of myristic acid. Cells were incubated under gentle agitation (150 rpm) and harvested 5 h after induction by centrifugation (5000 × g, 4°C, 30 min). Cell pellets were washed in 1 × PBS buffer, lysed in ice-cold RIPA buffer (50 mM Tris pH 7.4, 1% (v/v) NP-40, 1% (w/v) sodium deoxycholate, 150 mM NaCl, 0.5% (w/v) SDS and 1 × complete protease inhibitor cocktail (Roche)), sonicated, then centrifuged at 15,000 g for 30 min at 4°C. Samples were separated by SDS-PAGE and the gel washed briefly in water for in-gel fluorescent imaging. Gels were scanned with Cy3 filters to detect the TAMRA fluorophore.

SPR analysis

All peptides (> 90% pure) were obtained from GenicBio (Shanghai, China). Peptide-peptide interactions were studied by SPR on a Biacore 3000 (GE Lifesciences, Brøndby Denmark). Peptides were immobilized on a CM5 sensor chip (GE Lifesciences) using the Thiol Coupling Kit (GE Lifesciences) essentially according to the manufacturer's instructions. Briefly, peptides containing an N-terminal cysteine residue (SID2, GC-1, GC-2 and A3-C) were diluted to 50 μg/ml in 10 mM Na phosphate buffer (pH 4.0) and immobilized at surface densities ranging from 0.3 to 1.2 pmol/mm. Binding of SID1 and LZ1 was performed by injecting 40 μl analyte in concentrations ranging from 0.5 to 80 μM at a flow rate of 10 μl/min in 10 mM HEPES, 150 mM NaCl, 0.05% Tween-20 (pH 7.4) with either 5 mM EDTA or 50 μM CaCl₂. Flow cells were regenerated with two injections of 10 μl 100 mM glycine, 5 mM EDTA, 500 mM NaCl, 0.05% Tween-20 (pH 3.0) at 10 μl/min. Binding parameters were determined by fitting to a 1:1 interactions model using the BIAevaluation 4.1.1. (GE Lifesciences). Each parameter was determined by a duplicate run of duplicate factor 2 dilution series of dissolved peptide, ranging from 1.25 to 20 μM. As a minimum all experiments were conducted in triplicates of duplicates.

BLI analysis

Data were generated using the Octet RED96e system (Pall ForteBio) at 22°C, 1000 rpm orbital sensor agitation in 200 μl volume. NCS-1 or APOL3 were biotinylated with an EZ-Link NHS-PEG4-biotin (Thermo Fisher) by mixing in ratio 1:3 (protein:biotin) in 10 mM HEPES, 150 mM NaCl (pH 7.4) and incubating for 30 min at room temperature. For all assays streptavidin (SA) biosensors (Pall ForteBio) were used. Sensors pre-hydrated for 10 min in the BLI running buffer (BLI-RB: 10 mM HEPES, 150 mM NaCl, 50 μM CaCl₂, 0.05% Tween 20, 0.1% BSA, pH 7.4) followed by capture of biotinylated NCS-1, myr-NCS-1 (5 μg/ml in BLI-RB) or APOL3 (20 μg/ml in BLI-RB). Measurements with a loaded biosensor in absence of protein were used as reference and were subtracted from all binding curves. All sensorgrams were aligned using the last 5 s of baseline or second zero of association step. A Savitzky-Golay filter was applied to smooth the data. All APOL1 and APOL3 proteins were dissolved in 20 mM acetic acid (pH 3). For BLI measurements proteins were diluted with BLI-RB and the content of 20 mM acetic acid in the prepared sample was adjusted to be equal in the samples to be compared. For K_d determination, the buffer was 150 mM NaCl, 50 μM CaCl₂, 0.05% Tween 20, 0.1% BSA, 10 mM HEPES (pH 7.4). NCS-1 was loaded to 1.2 nm. The baseline was generated in BLI-RB over 300 s. Association with different concentrations of APOL3 (diluted in BLI-RB) was measured for 1200 s, and dissociation in BLI-RB was measured as well over 1200 s. Sensors were regenerated in 10 mM NaOH (pH 10), three times for 5 s. The sensorgrams were aligned using the last 5 s of baseline, fitted using 1:1 binding model (ForteBio Data Analysis 10.0 software), analyzing both association and dissociation. Binding curves were analyzed using Global (Full) fit with Rmax unlinked by sensor. R₂ was always above 0.99 and X₂ was lower than 0.65. The K_d was determined as an average of three experiments. For the binding of APOL1 variants/APOL3 to NCS-1 or APOL3, the buffer used was 100 mM NaCl, 50 μM CaCl₂, 0.05% Tween 20, 0.1% BSA, 200 mM HEPES (pH 7.4). The loading of NCS-1 was to 1.2 nm or APOL3 to 0.7-1 nm. The baseline was generated in BLI-RB over 120 s. Association with 0.2 μM APOL1, APOL1Δ, G1, G2, APOL1Δ1, APOL1 LZ1mut or APOL3 diluted in BLI-RB was measured for 600 s and dissociation in BLI-RB was measured as well over 600 s. In another experiment a mixture of 0.2 μM APOL3 and APOL1 variants in different molar ratios (1:1, 1:3 or 1:5) was used for association. For the binding of APOL3 to NCS-1 ± CHAPS, NP-40 or TWEEN 20, the buffer used was

150 mM NaCl, 50 μ M CaCl₂, 0.1% BSA, 10 mM HEPES (pH 7.4) \pm 1% CHAPS, 1% NP-40 or 0.05% TWEEN 20. NCS-1 was loaded to 1 nm and the baseline generated in BLI-RB containing 1% CHAPS, 1% NP-40 or 0.05% TWEEN 20 over 300 s. Association with 0.2 μ M APOL3 diluted in BLI-RB containing 1% CHAPS, 1% NP-40 or 0.05% TWEEN 20 was measured for 1000 s and dissociation in BLI-RB was measured as well over 1000 s. For the Ca²⁺-dependent binding of APOL3 to NCS-1, the buffer used was 150 mM NaCl (CaCl₂ free), 10 mM EGTA, 0.05% Tween 20, 0.1% BSA, 10 mM HEPES (pH 7.4). This buffer was used as a basic buffer and different amounts of CaCl₂ were added to achieve certain concentrations of free Ca²⁺ based on the MaxChelator Ca-EGTA Calculator v1.3 (Schoenmakers et al., 1992) using the following settings T = 22°C, 0.01 M EGTA, 0.15 N ionic strength (pH 7.4). NCS-1 was loaded to 1 nm and sensors were calibrated for 10 min in basic buffer before the measurements were started. The baseline was generated in corresponding buffers (\pm CaCl₂) over 600 s and association of 0.2 μ M APOL3 over 600 s.

For the competition assay of NCS-1 mutant for binding to APOL3, the buffer used was 150 mM NaCl, 50 μ M CaCl₂, 0.05% Tween 20, 0.1% BSA, 10 mM HEPES (pH 7.4). NCS-1 was loaded to 1-1.2 nm and the baseline generated in BLI-RB over 120 s. Association with 0.2 μ M APOL3 (diluted in BLI RB) or 0.2 μ M APOL3 mixed with 0.4 μ M NCS-1 WT or mutant was measured for 1000 s, and dissociation in BLI RB was measured as well over 1000s. For the binding of PI4KB and/or APOL3 to (N-myristoylated-) NCS-1, the buffer used was 150 mM NaCl, 50 μ M CaCl₂, 1% CHAPS, 0.1% BSA, 10 mM HEPES (pH 7.4). The loading of NCS-1 or myr-NCS-1 (5 μ g/ml in BLI-RB) was to 1.5-1.8 nm. The baseline was generated in BLI-RB over 60 s. Association with 0.1 μ M APOL3 (diluted in BLI RB) or 0.1 μ M APOL3 mixed with 0.1 μ M PI4KB or 0.1 μ M PI4KB (Thermo) alone was measured for 1000 s, and dissociation in BLI RB was measured as well over 1000 s. After this first dissociation there was a second association step with 0.1 μ M APOL3 or 0.1 μ M PI4KB in BLI RB over 1000 s followed by a second dissociation. For the binding of APOL1 or APOL1 Δ to NCS-1 or NCS-1-APOL3 complex, the buffer used was 150 mM NaCl, 50 μ M CaCl₂, 0.05% Tween 20, 0.1% BSA, 10 mM HEPES (pH 7.4). NCS-1 was loaded to 1 nm and the baseline generated in BLI-RB over 120 s. Association with 0.2 μ M APOL3, APOL1 or APOL1 Δ , diluted in BLI RB, was measured for 1000 s, followed by a second association of the same proteins in another order was measured over 1000 s.

Nile red-based hydrophobicity assay

In order to remove protein aggregates, recombinant APOL1, G1 or G2 were filtered and quantified directly after filtration using Nano-drop spectrometry. Concentrations were set at 1 μ M in 20 mM acetic acid and directly mixed with the hydrophobic dye Nile red (Sigma-Aldrich) (0.01 μ M in dimethyl sulfoxide). Fluorescence was monitored with a Nano Synergy Mx microplate reader with 550 nm and 630 nm as the excitation and emission wavelengths, respectively.

APOL1 variant quantification by qRT-PCR

Total RNA was purified using Direct-zol RNA kit from Zymo Research. The reverse transcription reaction was performed using 1 μ g of total RNA with the PrimeScript RT reagent Kit with gDNA Eraser, both from Takara. The qPCR reaction was performed with SYBR Premix Ex TaqII (Tli RNaseH Plus) from Takara. The cycling conditions were as following: 30 s at 95°C, then 40 cycles alternating 5 s at 95°C and 30 s at 62°C, then 15 s at 95°C. This amplification stage was followed by a melting curve. The sequences of the primers used to amplify APOL1 variants are the following: APOL1 Ex2-Forward: 5'-CCAGCTTTGCAATCATGAGATTC-3', APOL1 Ex4 Reverse: 5'-TTCCTCTGCCCTCACTCC-3', APOL1 Ex3-Forward:5'-ATGGAGGGAGCTGCTTTG-3', APOL1 Ex 3-5 Forward: 5'-TGCATCTGGGTGCAACAAA-3', APOL1 Ex5-Reverse: 5'-GATACTGCTCTCTGGGTCCAT-3'. Variant 2 was amplified using primers APOL1 Ex2-Forward and APOL1 Ex4 Reverse, variants 1 + 2 using primers APOL1 Ex3-Forward and Ex4 Reverse, variant 3 using APOL1 Ex 3-5 Forward and APOL1 Ex5-Reverse, and all variants using APOL1 Ex3-Forward and APOL1 Ex5-Reverse. The relative incidence of each variant was calculated as described (Camacho Londoño and Philipp, 2016).

Trypanolysis assays

In vitro measurements of APOL trypanolytic activity were performed as described (Fontaine et al., 2017; Lecordier et al., 2015). Briefly, trypanosomes were incubated at 5.10⁵/ml in HMI-9 supplemented medium at 37°C in a CO₂-equilibrated incubator. At the indicated times, living trypanosomes were counted in triplicate under the microscope. In these assays the volume of the APOL samples, in 20 mM acetic acid (pH 5), was kept constant so that there was no difference of acetic acid content between samples. Normalizations were performed to untreated controls.

PI4KB activity measurements

PI4KB activity was measured in an *in vitro* assay based on bioluminescent detection of ADP, as described (Tai et al., 2011). Briefly, recombinant PI4KB, APOL1, APOL3 and NCS-1 were diluted in 96 well-plates in kinase buffer (50mM NaCl, 2 mM MgCl₂, 25 μ g/ml BSA, 0.04% Triton X-100, 50 μ M DTT, 4 mM MnCl₂, 100 mM HEPES pH 7.5) containing either 0.5 mM EGTA, 0.1 mM CaCl₂ or 2 mM CaCl₂. After preincubation for 10 min at room temperature, the PI4KB substrate (PI:PS mix) was added. Reaction was started by addition of 40 μ M ATP and incubated for 40 min at 30°C. ADP was revealed by ADP-Glo kinase assay kit (Promega) following manufacturer's instruction. Background activity was evaluated by omission of either IP substrate, ATP or PI4KB, and was always lower than 0.1%.

Electrophysiology of APOL3

Planar lipid bilayers were formed by folding two lipid monolayers over a hole (110–150 μm in diameter) made in a 25 μm thick Teflon partition that separated two Teflon experimental chambers as described previously (Mlayeh et al., 2010). Briefly, the bilayer was made of either soybean phospholipid or 50% DOPC / 45% DOPE / 5% PI(4)P (w/w), purchased from Avanti. Lipids were dissolved in hexane to a final concentration of 2% (w/v). Ag/AgCl electrodes connected in series with a salt bridge (1M KCl in 1% agar) were used to connect the experimental chambers to the electronic equipment. The *trans* compartment was defined as the one connected to the ground (reference) and the voltage was applied to the *cis* compartment. For channel reconstitution into a planar lipid bilayer, recombinant APOL3 was added to the *cis* compartment (final concentration 400 ng/ml). All solutions were buffered with 10 mM HEPES (pH 7.5). Current recordings were performed using a BLM 120 amplifier (BioLogic, France). Data were filtered at 300Hz (5-poles linearized Tchebichev filter) and digitized at 44.1 kHz. The reversal potential (zero-current potential) was set to zero in presence of 1M KCl on both sides of the membrane. The *cis* compartment was afterward perfused three times its volume with a solution of 0.1 M KCl and the change in reversal potential (Erev) was recorded. The values of Erev were corrected for the liquid junction potential at salt bridges. The ideal selectivity toward monovalent cations is given by the Nernst equation: $E_{\text{rev}} = 59.1 \times \log_{10}(a_{\text{trans}} / a_{\text{cis}})$, where 'a' is the activity of the solution.

Cytosolic Ca^{2+} measurement

Cytosolic Ca^{2+} levels were monitored with Fura-2 AM as previously described (Bittremieux et al., 2017). Briefly, measurements were performed by seeding the different podocyte cell lines at 40,000 cells per well in 96-well plates (μclear , Greiner Bio-one). After differentiation as described above, the cells were loaded for 30 min with 1.25 μM Fura-2 AM at room temperature in modified Krebs solution containing 150 mM NaCl, 5.9 mM KCl, 1.2 mM MgCl_2 , 11.5 mM glucose, 1.5 mM CaCl_2 and 11.6 mM HEPES (pH 7.3), followed by a de-esterification step of 30 min in the absence of Fura-2 AM. Fluorescence was monitored on a FlexStation 3 microplate reader (Molecular Devices, Sunnyvale, CA, USA) by alternately exciting the Ca^{2+} indicator at 340 and 380 nm and collecting emitted fluorescence at 510 nm. For the dose-response experiments, EGTA (final concentration 3 mM) and increasing concentration of ATP (final concentration 0.3 up to 100 μM) were added. Ca^{2+} release from ER and non-ER stores (Golgi) was assessed by adding respectively EGTA (3mM final concentration), thapsigargin (500 nM final concentration) and finally ionomycin (10 μM final concentration). All traces are shown as the ratio of emitted fluorescence of Fura-2 (F340/F380) after a background correction. Concentration-response relationships were fitted to an asymmetric sigmoidal, five-parameter dose-response curve, which derives 50% efficient concentrations (EC_{50}) (GraphPad Prism software).

QUANTIFICATION AND STATISTICAL ANALYSIS

Statistical analysis was performed using Prism software (GraphPad). Immunofluorescence data were obtained from randomly selected cells from three independent experiments, and the images shown are representative of the majority of cells. Quantitative data were represented as means \pm standard deviation (SD); $n = 3$ unless otherwise indicated in the figure legends; no sample was excluded. Normality of the data was analyzed with the Shapiro-Wilk test. p values were calculated by the Student's t test and one-way ANOVA (post hoc Dunnett's test), for multiple and single comparisons of normally distributed data respectively, and by the Kruskal-Wallis (post hoc Dunn's test) for multiple comparisons of non-normally distributed data (* $p < 0.05$; ** $p < 0.01$; *** $p < 0.001$; **** $p < 0.0001$).

DATA AND CODE AVAILABILITY

The proteomics data generated during this study are available at the ProteomeXchange Consortium via with the PRIDE partner repository (dataset identifier PXD016851 and 10.6019/PXD016851).

Supplemental Information

APOL1 C-Terminal Variants May Trigger

Kidney Disease through Interference

with APOL3 Control of Actomyosin

Sophie Uzureau, Laurence Lecordier, Pierrick Uzureau, Dorle Hennig, Jonas H. Graversen, Fabrice Homblé, Pepe Ekulu Mfutu, Fanny Oliveira Arcolino, Ana Raquel Ramos, Rita M. La Rovere, Tomas Luyten, Marjorie Vermeersch, Patricia Tebabi, Marc Dieu, Bart Cuypers, Stijn Deborggraeve, Marion Rabant, Christophe Legendre, Søren K. Moestrup, Elena Levchenko, Geert Bultynck, Christophe Erneux, David Pérez-Morga, and Etienne Pays




Fig. S1

Figure S1. Editing of *APOL1* and/or *APOL3* affects the phenotype of independent podocyte clones (related to Figures 1 and 2)

(A) Poly(I:C)-induced cell death in different clones of the various podocyte lines. WT, n = 11;

1KO 1G3, n = 7; 1KO 5A4, n = 2; 1Δ 4B10, n = 5; 1Δ 3D8, n = 7; 1Δ 3G3, n = 10; 1Δ 4G6, n = 3; 3KO 2H2, n = 4; 3KO 6H6, n = 6; 3KO CI3, n = 3; 1+3KO 1G1, n = 3; 1+3KO 3D7, n = 8.

(B) Raw data of the poly(I:C)-mediated podocyte cell death measurements presented in Figs.

1C and Fig. S1A (ctrl= untreated control). Ctrl : WT, n = 15; 1KO 1G3, n = 14; 1KO 5A4, n = 6; 1Δ 4B10, n = 14; 1Δ 3D8, n = 12; 1Δ 3G3, n = 9; 1Δ 4G6, n = 12; 3KO 2H2, n = 16; 3KO 6H6, n = 28; 3KO CI3, n = 9; 1+3KO 1G1, n = 6; 1+3KO 3D7, n = 16. Poly(I:C) : WT, n = 18; 1KO 1G3, n = 14; 1KO 5A4, n = 6; 1Δ 4B10, n = 14; 1Δ 3D8, n = 12; 1Δ 3G3, n = 9; 1Δ 4G6, n = 12; 3KO 2H2, n = 16; 3KO 6H6, n = 28; 3KO CI3, n = 9; 1+3KO 1G1, n = 8; 1+3KO 3D7, n = 16.

(C) Cellular area of the different podocyte cell lines. WT, n = 179; 1KO 1G3, n = 168; 1KO

5A4, n = 61; 1Δ 4B10, n = 159; 1Δ 3D8, n = 157; 1Δ 3G3, n = 161; 1Δ 4G6, n = 158; 3KO 2H2, n = 87; 3KO 6H6, n = 102; 3KO CI3, n = 130; 1+3KO 3D7, n = 68; 1+3KO 1G1, n = 84.

(D) Cellular perimeter of the different podocyte cell lines. Same n values as panel C.

All quantitative results are expressed as means +/- SD.




Fig. S2

Figure S2. APOL1 and APOL3 exhibit important co-localization with ER and Golgi membranes (related to Figures 1 and 2)

- (A) Specificity of the immunolabelling with the anti-APOL1 and anti-V5 antibodies, as revealed by the strong reduction of staining, particularly cytoplasmic, with the anti-APOL1 antibody in the APOL1KO or APOL1+3KO cells, and by the absence of staining with the anti-V5 antibody in non-V5 tagged WT cells. Anti-V5 antibodies label C-terminal V5-tagged APOL3.
- (B) Immunofluorescence analysis of APOL1 and APOL3 co-localization. The graphs show the co-localization levels of cytoplasmic APOL1 and V5-APOL3, following removal of the APOL staining covered with the nuclear DAPI marker (error bars = SD). ctrl, n = 32; poly(I:C), n = 21.
- (C) Immunofluorescence analysis of APOL1 and APOL3 distribution with respect to ER and *trans*-Golgi markers (Calnexin and Golgin97, respectively). The graphs show the co-localization levels of cytoplasmic APOLs with ER or *trans*-Golgi markers, following removal of the APOL staining covered with the nuclear DAPI marker (error bars = SD). CytAPOL1/ Calnexin panel : ctrl, n = 30; poly(I:C), n = 24. CytAPOL1/ Golgin97 panel : ctrl, n = 23; poly(I:C), n = 23. CytAPOL3/ Calnexin panel : ctrl, n = 33; poly(I:C), n = 23. CytAPOL3/ Golgin97 panel : ctrl, n = 23; poly(I:C), n = 24.
- Cells were randomly selected from 3 independent experiments (ctrl = untreated cells; n = nucleus; scale bars = 20 μ m). In all images, the nuclear and cellular contours are indicated by dotted lines; when absent, these contours are outside the image surface.

APOL1

CRISPR
▼

MEGAALLRVSVLCIWMSALFLGVRVRAEEAGARVQQNVPSGTDGDPQSKPLGDWAAGTMDPESSIFIEDAIKYFKEKVSIQNLLLLLTDNEAWNGFVAAAE
LPRNEADELRKALDNLARQMIMKDKNWHDKGQQYRNWFLKEFPRLKSKLEDNIRRLRALADGVQKVHKGTTIANVVSGLSISGILTTLVGMGLAPFTEGGS
LVLLEPGMELGITAALTGITSSTIDYGKKWWTQAQAHDLVIKSLDKLKEVKEFLGENISNFLSLAGNTYQLTRGIGKDIRALRRARANLQSVPHASASRPRV
TEPISAESGEQVERVNEPSILEMSRGVKLTDVAPVSFFLVLDVVYLVYESKHLHEGAKSETAEELKKVAQELEEKLNILNNNYKILQADQEL

▲
CRISPR

APOL3

CRISPR
▼

MDSEKKRFTEEATKYFRERVSPVHLQILLTNNEAWKRFVTAELPRDEADALYEALKKLRTYAAIEDEYVQQKDEQFREWFLKEFPQVKRKIQESIEKLRAL
ANGIEEVHRGCTISNVVSSSTGAASGIMSLAGLVLPFTAGTSLALTAAGVGLGAASAVTGITTSIVEHSYTSSAEAEASRLTATSIDRLKVFEVMDITP
NLLSLLNNYEATQTIGSEIRAIRQARARARLPVTTWRISAGSGGQAERTIAGTTRAVSRGARILSATTSGIFLALDVVNLVYESKHLHEGAKSASAEELRR
QAQELEENLMELTQIYQRLNCPCHTH

Cell line	Allele 1	Allele 2
APOL1KO clone 1G3	RVQQNVPSGTDGDPQSKPLG ALGCWHHGPR *	RVQQNVPSGTDGDPQSKPLG ALGCWHHGPR *
APOL1KO clone 5A4	RVQQNVPSGTDGDPQSKPLGD KFTPLIILT *	WT
APOL1Δ clone 4B10	VLDVVYLV RIKALT *	VLDVVYLV RIKALT *
APOL1Δ clone 3D8 (hom)	VLDVVYLV RIKALT *	VLDVVYLV VRIKALT *
APOL1Δ clone 3G3 (het)	VLDVVYLV - SKHLHEGAKSETAEELKKVAQELEEKLNILNNNYKILQADQEL *	VLDVVYLV VRIKALT *
APOL1Δ clone 4G6	VLDVVYLV QSTYMRGQSQRQLRS *	VLDVVYLV QSTYMRGQSQRQLRS *
APOL3KO clone 2H2	DEADALYEALKKLRTYAA SRMFVVIQPLPLSLPILHTGPICPVRT *	DEADALYEALKKLRTYAA SRMFVVIQPLPLSLPILHTGPICPVRT *
APOL3KO clone 6H6	DEADALYEALKKLR T MRTNMCSRKMSSLGNGF *	DEADALYEALKKLR T FRTNMCSRKMSSLGNGF *
APOL3KO clone 3	DEADALYEALKKLRTYAA IEDEYVQQKDEQFREWFLKEFPQVKR KIQESIEKLRALANGIEEVHRGCTISNVVSSSTGAASGIMSLAGLV LAPFTAGTSLALTAAGVGLGAASAVTGITTSIVEHSYTSSAEAEAS RLTATSIDR *	DEADALYEALKKLRTYAA IEDEYVQQKDEQFREWFLKEFPQVKR KIQESIEKLRALANGIEEVHRGCTISNVVSSSTGAASGIMSLAGLV LAPFTAGTSLALTAAGVGLGAASAVTGITTSIVEHSYTSSAEAEAS RLTATSIDR *
APOL1KO (1G3) + APOL3KO clone 1G1	DEADALYEALKKLRTYA *	DEADALYEALKKLRTYA *
APOL1KO (1G3) + APOL3KO clone 3D7	DEADALYEALKKLRTYAA PRPLAPSPKPPDSPLQALPCPPHPLRLQV SSTSSRCDD *	DEADALYEALKKLRTYAA PRPLAPSPKPPDSPLQALPCPPHPLRLQV SSTSSRCDD *

Fig. S3

Figure S3. CRISPR/Cas9 editing of podocytes (related to all Figures)

In the APOL1 and APOL3 sequences, the coloured sections were edited in different podocyte cell lines as shown in the table.




A**B****C**

Fig. S4

Figure S4. Effect of *APOL* editing on actomyosin organization: additional information

(related to Figure 2)

(A) Cellular motility, as determined by single cell tracking of 30 randomly selected podocytes.

The mobility of APOL1 Δ hom podocytes was analysed following or not doxycycline-inducible addback expression of WT APOL1.

(B) ER shape, as determined by measurement of calnexin-immunostained structures using

MicroP software. WT, n = 47; 1KO, n = 8; 1 Δ hom, n = 22; 3KO, n = 14; 1+3KO, n = 44.

(C) Relative co-localization of the ER marker calnexin and INF2 with MYH9. Calnexin /

MYH9 panel: WT, n = 10; 1KO, n = 11; 1 Δ hom, n = 12; 3KO, n = 12; 1+3KO, n = 10.

INF2 / MYH9 panel: WT, n = 16; 1KO, n = 13; 1 Δ hom, n = 11; 3KO, n = 14; 1+3KO, n = 14.

Size bars = 2 μ m. All quantitative measurements are expressed as means +/- SD.

Figure S5. Effect of *APOL* editing on PI4KB activity: additional information (related to Figure 3)

- (A) Relative PI(4)P content in different clones of the *APOL1* Δ and *APOL3*KO cell lines, as determined by immunofluorescence with anti-PI(4)P antibodies. WT, n = 51; 1KO 1G3, n = 34; 1KO 5A4, n = 60; 1 Δ 4B10, n = 34; 1 Δ 3D8, n = 30; 1 Δ 3G3, n = 35; 1 Δ 4G6, n = 32; 3KO 2H2, n = 45; 3KO 6H6, n = 43; 3KO CI3, n = 38; 1+3KO 1G1, n = 18; 1+3KO 3D7, n = 53.
- (B) Relative Golgi extent in different clones of the *APOL1* Δ and *APOL3*KO cell lines, as determined by immunofluorescence with anti-Golgin97 antibodies. WT, n = 143; 1KO 1G3, n = 68; 1KO 5A4, n = 55; 1 Δ 4B10, n = 34; 1 Δ 3D8, n = 92; 1 Δ 3G3, n = 41; 1 Δ 4G6, n = 28; 3KO 2H2, n = 49; 3KO 6H6, n = 83; 3KO CI3, n = 31; 1+3KO 1G1, n = 51; 1+3KO 3D7, n = 82.
- (C) Relative co-localization of the PI(4)P phosphatase SAC-1 with the ER marker Calnexin and *trans*-Golgi marker Golgin97 in WT and *APOL1* Δ cells. SAC-1 / Calnexin panel: WT, n = 12; 1 Δ hom, n = 19. SAC-1 / Golgin97 panel: WT, n = 49; 1 Δ hom, n = 55.
- (D) Relative co-localization of NCS-1, PI4KB and the *trans*-Golgi marker GOLPH3 with cytoplasmic V5-tagged *APOL3*, and between NCS-1 and PI4KB in WT and *APOL1* Δ cells. NCS-1 / Cyt 3V5 panel: WT, n = 25; 1 Δ hom, n = 42. PI4KB / Cyt 3V5 panel: WT, n = 29; 1 Δ hom, n = 43. GOLPH3 / Cyt 3V5 panel: WT, n = 33; 1 Δ hom, n = 25. NCS-1 / PI4KB panel: WT, n = 30; 1 Δ hom, n = 41.

Size bars = 2 μ m. All quantitative measurements are expressed as means +/- SD.

A

Protein	Uniprot Reference	Molecular weight	WT	WT + poly (I:C)	1KO	1KO + poly (I:C)	1Δhom	1Δhom + poly (I:C)	3KO	3KO + poly (I:C)
MYH9	P35579	216 kDa	28	89	11	25	33	88	7	85
MYO6	Q9UM54	145 kDa	0	36	0	0	0	17	0	11
MYO1C	O00159	122 kDa	4	18	0	2	4	9	0	5
Gelsolin	B7Z6N2	85 kDa	2	17	0	0	8	11	0	10
Drebrin	Q16643	71 kDa	0	14	0	0	0	6	0	5
MYL9 or MYL12A (RLC)	Q6IBG1/J3QRS3	20 kDa/20 kDa	2	11	0	5	5	15	6	10
Coatmer subunit alpha	P53621	138 kDa	4	10	0	0	2	6	0	0
MYO5B	Q9ULV0	214 kDa	0	10	0	0	0	7	0	0
Tropomyosin (unique peptides)	see panel B	12 kDa	2	8	0	0	22	76	3	48
Protein phosphatase 1 regulatory subunit	B2RAH5	115 kDa	0	8	0	0	0	7	0	0
MYL6 (ELC)	H0Y43	29 kDa	6	7	0	6	8	14	4	11
MYO1D	O94832	116 kDa	2	7	0	0	0	5	0	7
Leucine-rich repeat flightless-interacting protein 2	Q9Y608	82 kDa	0	7	0	0	0	4	0	0
MYO1E	Q12965	127 kDa	5	6	4	6	0	2	0	0
Myosin phosphatase Rho-interacting protein (MPRIIP)	H0Y2S9	203 kDa	0	5	0	0	0	10	0	5
Protein flightless-1 homolog	Q13045	145 kDa	0	5	0	0	0	2	0	0
collagen alpha-1(I) chain	P02452	133 kDa	0	5	0	0	0	0	0	0
60S ribosomal protein L28	H0YKD8	19 kDa	2	4	0	0	3	4	0	2
Ankyrin	Q9P0K7	110 kDa	0	4	0	0	2	13	0	3
Coatmer subunit beta	P35606	102 kDa	0	4	0	0	0	4	0	0
Apolipoprotein L 1 (APOL1)	B2R9E5	41/38 kDa	0	4	0	0	0	2	2	9

B

	Uniprot Reference	WT	WT + poly (I:C)	1KO	1KO + poly (I:C)	1Δhom	1Δhom + poly (I:C)	3KO	3KO + poly (I:C)
tropomyosin alpha-3 chain isoform Tpm3.1cy	B2RDE1	0	4	0	0	4	23	0	14
tropomyosin alpha-4 chain isoform Tpm4.2cy	B4DVY2	2	5	0	0	7	18	0	14
tropomyosin beta chain isoform Tpm2.4	B4E3P1	0	0	0	0	0	19	0	14
Tropomyosin alpha-1 chain isoform Tpm1.9cy	H7BYY1	0	0	0	0	0	26	0	17
tropomyosin beta chain isoform Tpm2.3	P07951-3	0	0	0	0	0	15	0	11
tropomyosin alpha-1 chain isoform Tpm1.3sm	P09493-8	0	0	0	0	9	27	0	15

C

GO biological process	Fold enrichment	+/-	P Value
Actin filament-based process (GO:0030029)	13.87	+	5.02E-04
Vesicle-mediated transport (GO:0016192)	5.86	+	1.41E-03
Cellular localization (GO:0051641)	5.76	+	8.68E-05

GO molecular function	H. sapiens	Found	Expected	enrichment	+/-	P value
Microfilament motor activity	22	6	0.03	>100	+	6.04E-10
Actin-dependent ATPase activity	12	3	0.01	>100	+	1.11E-03
Motor activity	135	6	0.16	37.28	+	2.96E-05
Actin filament binding	137	6	0.16	36.74	+	3.22E-05
Calmodulin binding	188	7	0.22	31.23	+	5.06E-06
Actin binding	404	11	0.48	22.84	+	1.23E-09
Cadherin binding	294	7	0.35	19.97	+	1.07E-04
Cell adhesion molecule binding	449	7	0.54	13.08	+	1.84E-03
Cytoskeletal protein binding	853	11	1.02	10.82	+	3.44E-06
Unclassified	3792	2	5.52	0.44	-	0.00E00

Fig. S6

Figure S6. APOL1 is associated with actomyosin components (related to Figure 2)

(A) Mass spectrometry analysis of proteins co-immunoprecipitated with anti-APOL1 antibodies in different podocyte cell lines, incubated or not with poly(I:C). The immunoprecipitates were treated with 1% NP-40.

(B) Details of tropomyosin isoforms immunoprecipitated with APOL1 (peptides common to different isoforms are listed several times).

(C) Functional analysis of immunoprecipitated components.

Figure S7. Y2H screening for APOL1-interacting proteins mostly reveals intramolecular interactions (related to Figure 4)

(A) cDNA was synthesized on pooled poly(A)+ RNA (50:50) from untreated and poly(I:C)-treated podocytes.

(B) The podocyte cDNA library was cloned in a prey vector and transfected in *Saccharomyces cerevisiae*.

(C) Different regions of the APOL1 sequence in a bait vector were used for the screening of podocyte interacting sequences. For bait 1 and bait 2, respectively 57.5 million interactions in the presence of 5 mM HIS3 inhibitor 3-amino-1,2,4-triazole (3-AT) and 67.6 million interactions in 0.5 mM 3-AT were analysed.

(D) List of the genes identified following the screening with the different baits (SID = smallest interacting domain; score: A = very high, B = high, C = good and D = moderate confidence in the interaction).


(E) Sequence comparison of the APOL1 and APOL2 SIDs (asterisks = identical amino acids; underlined violet amino acids: hydrophobic residues in HCs; underlined pink amino acids: positions “a” and “d” of heptads in LZs).

A


Interaction Matrix				Selection Medium							
N° / Type	Bait*	Prey**		DO-2	DO-3	DO-3 + 1mM 3AT	DO-3 + 5mM 3AT	DO-3 + 10mM 3AT	DO-3 + 50mM 3AT	DO-3 + 100mM 3AT	DO-3 + 200mM 3AT
1	Positive control	smad	smurf	+	+	+	+	+	+	+	+
2	Negative control	pB27ø	pP7ø	+	-	-	-	-	-	-	-
3	Negative control	pB27ø	APOL1 Cter wt	+	-	-	-	-	-	-	-
4	Negative control	APOL1 Nter	pP7ø	+	-	-	-	-	-	-	-
5	Interaction	APOL1 Nter	APOL1 Cter wt	+	+	+	+	+	+	+	+
6	Negative control	pB27ø	APOL1 Cter Mut G1	+	-	-	-	-	-	-	-
7	Interaction	APOL1 Nter	APOL1 Cter Mut G1	+	+	+	+	+	+	+	+
8	Negative control	pB27ø	APOL1 Cter Mut G2	+	-	-	-	-	-	-	-
9	Interaction	APOL1 Nter	APOL1 Cter Mut G2	+	+	+	+	+	+/-	-	-

* APOL1 Nter : [aa 60-187]


** APOL1 Cter : [aa 236-398/396]



B



C



D

Interaction Matrix			Selection Medium	
N° / Type	Bait	Prey	DO-2	DO-3
1	Positive control	smad	+	+
2	Negative control	pB27ø	+	-
3	Negative control	APOL1 LZ1mut	+	-
4	Interaction	APOL1 LZ1mut	+	-
5	Negative control	pB27ø	+	-
6	Interaction	APOL1 LZ1mut	+	-
7	Negative control	pB27ø	+	-
8	Interaction	APOL1 LZ1mut	+	-

APOL1 LZ1mut: L111Q/L115Q/L118Q (aa 60-187)

E

Interaction Matrix			Selection Medium	
N° / Type	Bait	Prey	DO-2	DO-3
1	Positive control	smad	+	+
2	Negative control	APOL3 null mut	+	-
3	Negative control	APOL1 null mut	+	-
4	Negative control	APOL1Δ null mut	+	-
5	Negative control	pB27ø	+	-
6	Interaction	APOL3 null mut	+	+
7	Interaction	APOL1 null mut	+	-
8	Interaction	APOL1Δ null mut	+	-

APOL3 null mut: L137Q/A138Q/P139S/G143S

APOL1/1Δ null mut: P198S/G202S/G203S





Fig. S8


Figure S8. APOLs interactions in the Y2H system: additional features (related to Figures 4 and S7)

- (A) Strength of interactions between APOL1 SIDs, as measured by the resistance of the complexes to increasing concentrations of 3-AT. Positive and negative controls are indicated. Numbers above the lanes at the right correspond to those in the table at the left.
- (B) Strength of interactions between SID1 and C-terminal APOL3 sequence, measured as in (A). Numbers above the lanes at the right correspond to those in the table at the left.
- (C) Trypanolytic assays involving different APOL3 and APOL1 mutants used in this work, performed as a way to check protein activity following mutagenesis (means +/- SD; n = 3).
- (D) Interactions between the 60-187 fragment of the LZ1mut mutant of APOL1 and different fragments containing SID2, all identified as strongly interacting with the 60-187 fragment of WT APOL1 in the initial cDNA library screening.
- (E) Interactions of APOL3 or APOL1 null mutants with NCS-1. Numbers in the panel at the right correspond to those in the table at the left.


A




B



C



D



E




Fig. S9

Figure S9. Characterization of intracellular APOL1 (related to Figure 5)

(A) Immunogold detection of intracellular APOL1 in WT podocytes. Gold particles in the cytoplasm, which identify the localization of APOL1, were false-coloured in red. Control experiments on APOL1KO cells did not reveal any cytoplasmic labelling (not shown). Left panels illustrate clustered labelling close to the mitochondrion (m = mitochondrion); panels at the right exhibit cytosolic labelling. Bars = 200 nm.

(B) Western blot analysis of APOL1 in either normal human serum (NHS) (0.2 μ l) or WT podocytes extracts (10 μ g). NHS was added to extracts from either 1KO or WT podocytes to avoid any electrophoretic mobility difference linked to differential protein loading, also allowing the demonstration that intracellular APOL1 (arrow) migrates between the two APOL1 bands in NHS.

(C) qRT-PCR analysis of APOL1 isoforms (means \pm SD; n = 3).

(D) Prediction of signal peptide in APOL1 isoform 3, using the SignalP-5.0 program (Expasy).


(E) Comparison of the predicted cleavage sites in WT APOL1 (blue) or isoform 3 (green).

A




Gene name	score	SID (amino acid)	times found
PSME1	A	93-111	16
BCAR1	A	794-810	8
APOL1	B	367-392	5
APOL3	B	295-327	5
CAP1	B	15-78	6
HNRNPH1	B	36-245	6
LAMB1	B	1223-1279	3
ADAMTS1	C	205-288	3
BAP1	C	595-729	3
GDI2	C	370-445	5
NOP56	C	152-208	5
SPTBN1 var1	C	287-325 / 571-605 / 941-1023 / 1796-1936	9
UBAC1	C	28-312	4
WTAP	C	1-170	3
64 preys have been identified with score D			

B



C



Gene name	score	SID (amino acid)	times found
NCS-1	A	17-189	33
PSMD2	A	461-619	18
TRIM8	A	210-302	7
AOE37-2	B	64-223	5
APOL1	C	57-164	2
CDC42BPB	D	23-171	2
HEG1	D	914-1148	1
HPCAL1	D	7-193	1
KCNIP1	D	53-227	4
PICALM	D	1-230	6
SP140L	D	252-499	1
YLPM1	D	1185-1469	1

Fig. S10

Figure S10. Y2H screening for APOL3-interacting proteins does not reveal intramolecular interaction, but identifies NCS-1 (related to Figures 4 and S7)

- (A) Y2H screening experiment conducted with the 1-124 fragment of APOL3. 51.2 million interactions in 20 mM 3-AT were analysed. Score: A = very high, B = high, C = good and D = moderate confidence in the interaction
- (B) Evaluation of the potential of APOL1 and APOL3 N-terminal regions to form coiled-coils (COILS program, Expasy). Pink colours highlight the amino acids at positions “a” and “d” of heptad repeats in LZs (see Fig. 4).
- (C) Y2H screening experiment conducted with the complete sequence of the APOL3 null mutant (L137Q/A138Q/P139S/G143S) (Fontaine et al., 2017). 114 million interactions without 3AT were analysed. Same scores as in (A).




Fig. S11

Figure S11. Binding of APOL1 variants and NCS-1 to APOL3: additional features

(related to Figure 5)

- (A) BLI measurements of interaction between bound NCS-1 and APOL3 or APOL3 HC2-like mutant HCmut (n = 3).
- (B) BLI measurements of interaction between bound NCS-1 and APOL3, in the presence or not of WT or mutant NCS-1 in a molar ratio of 1:2 (APOL3 : NCS-1) (n = 3).
- (C) BLI measurements of interaction between bound NCS-1 and various concentrations of APOL3, with fitted curves (red) for determination of APOL3/NCS-1 binding affinity (n = 3).
- (D) Generation of N-myristoylated NCS-1. Recombinant NCS-1 was synthesized in *E. coli* together or not with human N-myristoyl-transferase (hsNMT1) and either myristic acid or its alkynyl analogue 13-tetradecynoic acid. Fluorescent N-myristoylated NCS-1 was detected by binding of the TAMRA fluorophore to NCS-1-bound 13-tetradecynoic acid. Coomassie blue staining allows detection of NCS-1 (arrowhead), in total *E. coli* extracts or purified recombinant protein fraction.
- (E) BLI measurements of interaction between bound N-myristoylated NCS-1 and APOL3 or PI4KB, added sequentially as indicated (n = 3).
- (F) BLI measurements of interaction between bound NCS-1 and various APOLs, added sequentially as indicated (n = 3).
- (G) BLI measurements of interaction between bound NCS-1 and APOL3, alone or with different molar ratios of G1 or G2 (n = 3).

All quantitative measurements are expressed as means +/- SD.








Fig. S12

Figure S12. Generation of urine *APOL1* WT and *G2/G2* podocyte cell lines (related to Figure 7)

- (A) Top panel: identification of WT and variant *APOL1* genotypes by trypanolytic assays of different human sera on *T. rhodesiense*, *T. gambiense* and *T. brucei*. The parasites were incubated with 20% fetal calf serum (FCS), normal human serum (NHS) or G2 human serum, and with sera from humans with various *APOL1* genotypes. The parasite growth ratio after overnight incubation is expressed as a percentage of control growth in FCS. Sera 1, 3, 12 and 15 (encircled) exhibited G1 or G2 phenotypes. Bottom panel: western blot serum analysis with anti-*APOL1*.
- (B) Western blot sera analysis with anti-haptoglobin (Hp), meant to evaluate if Hp variation could explain the relative resistance to *T. rhodesiense* (Lecordier et al., 2015)
- (C) Genotype of *APOL1* WT and *G2/G2* podocytes upon amplification of exon 7.
- (D) Immunofluorescence staining for podocyte-specific proteins synaptopodin, podocin and podocalyxin with the nuclear staining DAPI (blue). Scale bar: 50 μm .

A



B




Fig. S13

Figure S13. Control of PI4KB and actomyosin by APOLs: a model (related to all Figures)

(A) APOL control of PI(4)P synthesis. APOL1 and APOL3 are inserted in the Golgi membrane where they can exhibit K^+ channel activity. PI4KB is anchored to Golgi membranes notably through interactions with the ACBD3/giantin complex (Klima et al., 2016) and synthesizes PI(4)P that is crucial for secretion (Bishé et al., 2012; de Barry et al., 2006; Dippold et al., 2009; Haynes et al., 2005; Kuna and Field, 2019; Tokuda et al., 2014; Zhao et al., 2001). The N-myristoylated form of NCS-1 activates PI4KB through a direct interaction (Zhao et al., 2001). APOL3 interacts with NCS-1 irrespective of NCS-1 myristoylation, through Ca^{2+} -dependent hydrophobic contacts involving its C-terminal hydrophobic cluster. These contacts evoke those between the yeast NCS-1 homologue Frq1 and the PI4KB homologue Pik1 (Pandalaneni et al., 2015; Strahl et al., 2003). Whereas APOL1 or APOL1 G1/G2 variants can hinder association of APOL3 with NCS-1 (dotted or plain red line respectively), APOL1 Δ can bind to APOL3 and inactivate this protein without dissociating the APOL3/NCS-1 complex. In APOL1 Δ and APOL3KO cells where APOL3 is no longer active, PI4KB is inhibited and the level of Golgi PI(4)P is reduced. However, in the absence of both APOL1 and APOL3, PI4KB appears to be active. In addition to the control of PI4KB, APOL1 and APOL3 also influence the levels of Ca^{2+} in Golgi stores, possibly through their redundant K^+ channel activity. Hypotheses attempting to explain these observations are presented in the discussion (CALN = PI4KB inhibitor calneuron).

(B) Interplay between APOLs, PI(4)P and the NM2A myosin. APOL1 and APOL3 bind to and co-localize with PI(4)P, and indirectly associate with the fission and secretion motor NM2A. Multiple pathways connect PI(4)P with NM2A. In particular, (i) the PI(4)P-binding protein GOLPH3 binds to the NM2A-interacting protein MYO18A (Billington et

al., 2015; Dippold et al., 2009; Kuna and Field, 2019; Taft et al., 2013), (ii) the phosphoinositide-binding GTPase-activating protein ASAP1 interacts with the ARF1-binder GOLPH3 and with NM2A (Chen et al., 2016; Kam et al., 2000; Rodrigues et al., 2016; Tu et al., 2012), (iii) the NM2A heavy chain MYH9 directly binds to anionic phospholipids (Liu et al., 2016), and (iv) PI4KIII β and PI4P initiate autophagy by recruiting ATG9, ARFIP2 and NM2A at the Golgi (Judith et al., 2019). Thus, affecting Golgi PI(4)P level influences actomyosin organization, vesicular trafficking and autophagy (review in Tan and Brill, 2014).

Table S1.
Genome sequencing of CRISPR/Cas9-generated podocyte clones (related to Fig. S3)

A. CRISPR/Cas9 target sites.

Target	Protospacer	PAM (-NGG)
<i>APOL2</i>	TGTGCTGCTGGTCTTTATCG	TGG
<i>APOL3</i> exon 5	TAGAACATATGCAGCTATTG	AGG
<i>APOL3</i> exon 5	AACCAGCATTGACCGATTGA	AGG
<i>APOL1</i> exon 3	AAGTAAGCCCCTCGGTGACT	GGG
<i>APOL1</i> exon 5	AGTGCTTTGATTTCGTACACG	AGG

B. Sequencing coverage of the podocyte genomes.

	WT	1KO	1Δhet	1Δhom	3KO
% cov. 10x	98,46	98,60	97,91	98,28	98,39
% cov. 20x	89,36	89,89	81,58	84,58	87,94
% cov. 30x	44,71	50,50	32,16	36,76	52,77
Average coverage	29,44	30,67	26,64	27,84	30,87
St. dev. coverage	34,97	36,45	32,88	34,18	35,88

C. Mutations in *APOL1* and *APOL3* detected following whole genome sequencing.

Sample	Gene	Position (chr22)	cDNA position	CDS position	Type	Modification
APOL1KO	<i>APOL1</i>	36257381	484/3017	210/1245	deletion	AC
APOL1KO	<i>APOL1</i>	36257381	484/3017	210/1245	insertion	C
APOL1Δhom	<i>APOL1</i>	36265858	1345/3017	1071/1245	deletion	TAAGCTTCTTTCTT GTGCTGGATGTA GTCTACCTCGTGT ACGAATCAAA
APOL1Δhom	<i>APOL1</i>	36265893	1382/3017	1108/1245	deletion	GT
APOL1Δhom	<i>APOL1</i>	36265895	1383/3017	1109/1245	insertion	G
APOL1Δhet	<i>APOL1</i>	36265895	1383/3017	1109/1245	insertion	G
APOL1Δhet	<i>APOL1</i>	36265895	1383/3017	1109/1245	deletion	GTACGA
APOL3KO	<i>APOL3</i>	36141621	827/2124	789/1209	deletion	A

D. On-target and off-target homozygous (minimal 10-fold coverage) and heterozygous (minimal 20-fold coverage) SNPs with moderate or high impact.

		1KO	1Δhom	1Δhet	3KO
Homozygous SNPs	Total number of SNPs (moderate impact/high impact)	0(0/0)	0(0/0)	3(0/0)	1(1/0)
	Genes affected by moderate or high impact SNPs				HEG1 (moderate impact)
Heterozygous SNPs	Total number of SNPs (moderate impact/high impact)	5140(12/0)	9133(18/1)	6605(21/1)	28007(88/4)
	Genes affected by high impact SNPs		ERBB3	IGSF1	C2orf91 HAAO DSCAM EXOC1

E. On-target and off-target homozygous (minimal 10-fold coverage) and heterozygous (minimal 20-fold coverage) INDELS with moderate or high impact.

		1KO	1Δhom	1Δhet	3KO
Homozygous INDELS	Total number of INDELS (moderate impact/high impact)	10(0/1)	23(0/1)	25(0/0)	21(0/1)
	Genes affected by moderate or high impact INDELS	APOL1 (high impact)	APOL1 (high impact)	/	APOL3 (high impact)
Heterozygous INDELS	Total number of INDELS (moderate impact/high impact)	20542 (3/5)	15710 (4/9)	17545 (2/9)	23781 (5/4)
	Genes affected by high impact INDELS	PRPF3 GEMIN2 GOLGA6L2 ANKRD36 IL32	MED1 POT1 GOLGA6L2 ANKRD36 IL32 RUBCN ZNF879 TCEB3CL ZBTB10	MED1 POT1 GOLGA6L2 ANKRD36 LINC00368 TCEB3CL LOC63930 APOL1 GEMIN2	MED1 POT1 GOLGA6L2 ANKRD36